CA2176203C - Water soluble active sulfones of poly(ethylene glycol) - Google Patents
Water soluble active sulfones of poly(ethylene glycol) Download PDFInfo
- Publication number
- CA2176203C CA2176203C CA002176203A CA2176203A CA2176203C CA 2176203 C CA2176203 C CA 2176203C CA 002176203 A CA002176203 A CA 002176203A CA 2176203 A CA2176203 A CA 2176203A CA 2176203 C CA2176203 C CA 2176203C
- Authority
- CA
- Canada
- Prior art keywords
- moiety
- sulfone
- active
- polymer
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
- C08G65/326—Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Abstract
A poly(ethylene glycol) derivative is disclosed that is activated with a sul fone moiety for selective attachment to thiol moieties on molecules and surfaces. The activated PEG is water soluble, hydrolyticall y stable for extended periods, and forms hydrolytically stable linkages with thiol moieties. The linkages generally are not reversib le in reducing environments. The PEG derivative is usefu l for modifying the characteristics of substances including modifying biologically active molecules and surfaces for biocompatibility. Met hods for synthesizing the active PEG and for preparing conjugates of the active PEG a nd other substances, including biologically active subst ances, are also disclosed.
Description
WATER S01_UBLE ACTIVE SULFONES OF POLYETHYLENE GLYCOL) Field of the Invention This invention relates to active derivatives of polyethylene glycol) and related hydrophilic polymers and to methods for their synthesis for use in modifying the characteristics of surfaces and molecules.
Background of the Invention Polyethylene glycol) ("PEG") has been studied for use in pharmaceuticals, on artificial implants, and in other_- applications where biocompatibility is of importance. Various derivatives of polyethylene glycol) ("PEG derivatives") have been proposed that have an active moiety for permitting PEG
to be attached to pharmaceuticals and implants and to molecules and surfaces generally to modify the physical or chemical characteristics of the molecule or surface.
For example, PEG derivatives have been proposed for coupling PEG to surfaces to control wetting, static buildup, and attachment of other types of molecules to the surface, including proteins or protein residues. More specifically, PEG derivatives have been proposed for attachment to the surfaces of plastic contact lenses to reduce the buildup of proteins and clouding of vision. PEG derivatives have 2 ~ ~ ~ 2 0 3 pC'T~S94113013 been proposed for attachment to artificial blood vessels to reduce protein buildup and the danger of blockage. PEG derivatives have been proposed for immobilizing proteins on a surface, as in enzymatic catalysis of chemical reactions.
In still further examples, PEG derivatives have been proposed for attachment to molecules, including proteins, for protecting the molecule from chemical attack, to limit adverse side effects of the molecule, or to increase the size of the molecule, thereby potentially to render useful substances that have some medicinal benefit, but are otherwise not useful or are even harmful to a living organism. Small molecules that normally would be excreted through the kidneys are maintained in the blood stream if their size is increased by attaching a biocompatible PEG
derivative. Proteins and other substances that create an immune response when injected can be hidden to some degree from the immune system by coupling of a PEG
molecule to the protein.
PEG derivatives have also been proposed for affinity partitioning of, for example, enzymes from a cellular mass. In affinity partitioning, the PEG
derivative includes a functional group for reversible coupling to an enzyme that is contained within a cellular mass. The PEG and enzyme conjugate is separated from the cellular mass and then the enzyme is separated from the PEG derivative, if desired.
Coupling of PEG derivatives to proteins illustrates some of the problems that have been encountered in attaching PEG to surfaces and molecules.
For many surfaces and molecules, the number of sites available for coupling reactions with a PEG derivative is somewhat limited. For example, proteins typically have a limited number and distinct type of reactive sites available for coupling. Even more problematic, some of the reactive sites may be responsible for the protein's biological activity, as when an enzyme catalyzes certain chemical reactions. A PEG derivative that attached to a sufficient number of such sites could adversely affect the activity of the protein.
Reactive sites that form the loci for attachment of PEG derivatives to proteins are dictated by the protein's structure. Proteins, including enzymes, are built of various sequences of alpha-amino acids, which have the general structure HZN-CHR-COOH.
The alpha amino moiety (HZN- ) of one amino acid j oins to the carboxyl moiety (--COOH) of an adjacent amino acid to form amide linkages, which can be represented as -(NH-CHR-CO)n-, where n can be hundreds or thousands.
The fragment represented by R can contain reactive sites for protein biological activity and for attachment of PEG derivatives.
For example, in lysine, which is an amino acid forming part of the backbone of most proteins, an -NH2 moiety is present in the epsilon position as well as in the alpha position. The epsilon -NHZ is free for reaction under conditions of basic pH. Much of the art has been directed to developing PEG derivatives for attachment to the epsilon -NH2 moiety of the lysine fraction of a protein.. These PEG derivatives all have in common that the lysine amino acid fraction of the protein typically is :Lnactivated, which can be a drawback where lysine is important to protein activity.
Zalipsky U.S. Patent No. 5,122,614 discloses that PEG molecules activated with an oxycarbonyl-N-dicarboximide functional group can be attached under aqueous, basic conditions by a urethane linkage to the amine group of a polypeptide. Activated PEG-N-succinimide carbonate is said to form stable, hydrolysis-resistant urethane linkages with amine groups. The amine group is shown to be more reactive at basic pHs of from about 8.0 to 9.5, and reactivity falls off sharply at lower pH. However, hydrolysis of the uncoupled PEG derivative also increases sharply at pH's of 8.0 to 9.5. Zalipsky avoids the problem of an increase in the rate of reaction of the uncoupled PEG
derivative with water by using an excess of PEG
derivative to bind to the protein surface. By using an excess, sufficient reactive epsilon amino sites are bound with PEG to modify the protein before the PEG
derivative has an opportunity to become hydrolyzed and unreactive.
Zalipsky's method is adequate for attachment of the lysine fraction of a protein to a PEG derivative at one active site on the PEG derivative. However, if the rate of hydrolysis of the PEG derivative is substantial, then it can be problematic to provide attachment at more than one active site on the PEG
molecule, since a simple excess does not slow the rate of hydrolysis.
For example, a linear PEG with active sites at each end will attach to a protein at one end, but, if the rate of hydrolysis is significant, will react with water at the other end to become capped with a relatively nonreactive hydroxyl moiety, represented structurally as -OH, rather than forming a "dumbbell"
molecular structure with attached proteins or other desirable groups on each end. A similar problem arises if it is desired to couple a molecule to a surface by a PEG linking agent because the PEG is first attached to the surface or couples to the molecule, and the opposite end of the PEG derivative must remain active for a subsequent reaction. If hydrolysis is a problem, then the opposite end typically becomes inactivated.
Also disclosed in Zalipsky U.S. Patent No.
Background of the Invention Polyethylene glycol) ("PEG") has been studied for use in pharmaceuticals, on artificial implants, and in other_- applications where biocompatibility is of importance. Various derivatives of polyethylene glycol) ("PEG derivatives") have been proposed that have an active moiety for permitting PEG
to be attached to pharmaceuticals and implants and to molecules and surfaces generally to modify the physical or chemical characteristics of the molecule or surface.
For example, PEG derivatives have been proposed for coupling PEG to surfaces to control wetting, static buildup, and attachment of other types of molecules to the surface, including proteins or protein residues. More specifically, PEG derivatives have been proposed for attachment to the surfaces of plastic contact lenses to reduce the buildup of proteins and clouding of vision. PEG derivatives have 2 ~ ~ ~ 2 0 3 pC'T~S94113013 been proposed for attachment to artificial blood vessels to reduce protein buildup and the danger of blockage. PEG derivatives have been proposed for immobilizing proteins on a surface, as in enzymatic catalysis of chemical reactions.
In still further examples, PEG derivatives have been proposed for attachment to molecules, including proteins, for protecting the molecule from chemical attack, to limit adverse side effects of the molecule, or to increase the size of the molecule, thereby potentially to render useful substances that have some medicinal benefit, but are otherwise not useful or are even harmful to a living organism. Small molecules that normally would be excreted through the kidneys are maintained in the blood stream if their size is increased by attaching a biocompatible PEG
derivative. Proteins and other substances that create an immune response when injected can be hidden to some degree from the immune system by coupling of a PEG
molecule to the protein.
PEG derivatives have also been proposed for affinity partitioning of, for example, enzymes from a cellular mass. In affinity partitioning, the PEG
derivative includes a functional group for reversible coupling to an enzyme that is contained within a cellular mass. The PEG and enzyme conjugate is separated from the cellular mass and then the enzyme is separated from the PEG derivative, if desired.
Coupling of PEG derivatives to proteins illustrates some of the problems that have been encountered in attaching PEG to surfaces and molecules.
For many surfaces and molecules, the number of sites available for coupling reactions with a PEG derivative is somewhat limited. For example, proteins typically have a limited number and distinct type of reactive sites available for coupling. Even more problematic, some of the reactive sites may be responsible for the protein's biological activity, as when an enzyme catalyzes certain chemical reactions. A PEG derivative that attached to a sufficient number of such sites could adversely affect the activity of the protein.
Reactive sites that form the loci for attachment of PEG derivatives to proteins are dictated by the protein's structure. Proteins, including enzymes, are built of various sequences of alpha-amino acids, which have the general structure HZN-CHR-COOH.
The alpha amino moiety (HZN- ) of one amino acid j oins to the carboxyl moiety (--COOH) of an adjacent amino acid to form amide linkages, which can be represented as -(NH-CHR-CO)n-, where n can be hundreds or thousands.
The fragment represented by R can contain reactive sites for protein biological activity and for attachment of PEG derivatives.
For example, in lysine, which is an amino acid forming part of the backbone of most proteins, an -NH2 moiety is present in the epsilon position as well as in the alpha position. The epsilon -NHZ is free for reaction under conditions of basic pH. Much of the art has been directed to developing PEG derivatives for attachment to the epsilon -NH2 moiety of the lysine fraction of a protein.. These PEG derivatives all have in common that the lysine amino acid fraction of the protein typically is :Lnactivated, which can be a drawback where lysine is important to protein activity.
Zalipsky U.S. Patent No. 5,122,614 discloses that PEG molecules activated with an oxycarbonyl-N-dicarboximide functional group can be attached under aqueous, basic conditions by a urethane linkage to the amine group of a polypeptide. Activated PEG-N-succinimide carbonate is said to form stable, hydrolysis-resistant urethane linkages with amine groups. The amine group is shown to be more reactive at basic pHs of from about 8.0 to 9.5, and reactivity falls off sharply at lower pH. However, hydrolysis of the uncoupled PEG derivative also increases sharply at pH's of 8.0 to 9.5. Zalipsky avoids the problem of an increase in the rate of reaction of the uncoupled PEG
derivative with water by using an excess of PEG
derivative to bind to the protein surface. By using an excess, sufficient reactive epsilon amino sites are bound with PEG to modify the protein before the PEG
derivative has an opportunity to become hydrolyzed and unreactive.
Zalipsky's method is adequate for attachment of the lysine fraction of a protein to a PEG derivative at one active site on the PEG derivative. However, if the rate of hydrolysis of the PEG derivative is substantial, then it can be problematic to provide attachment at more than one active site on the PEG
molecule, since a simple excess does not slow the rate of hydrolysis.
For example, a linear PEG with active sites at each end will attach to a protein at one end, but, if the rate of hydrolysis is significant, will react with water at the other end to become capped with a relatively nonreactive hydroxyl moiety, represented structurally as -OH, rather than forming a "dumbbell"
molecular structure with attached proteins or other desirable groups on each end. A similar problem arises if it is desired to couple a molecule to a surface by a PEG linking agent because the PEG is first attached to the surface or couples to the molecule, and the opposite end of the PEG derivative must remain active for a subsequent reaction. If hydrolysis is a problem, then the opposite end typically becomes inactivated.
Also disclosed in Zalipsky U.S. Patent No.
5,122,614 are several other PEG derivatives from prior patents. PEG-succinoyl-N-hydroxysuccinimide ester is said to form ester linkages that have limited stability in aqueous media, thus indicating an undesirable short half-life for this derivative. PEG-cyanuric chloride.
WO 95!13312 PCTIUS94/13013 _S_ is said to exhibit an undesirable toxicity and to be non-specific for react: ion with particular functional groups on a protein. The PEG-cyanuric chloride derivative may therefore have undesirable side effects and may reduce protein activity because it attaches to a number of different types of amino acids at various reactive sites. PEG-phenylcarbonate is said to produce toxic hydrophobic phenol residues that have affinity for proteins. PEG act=ivated with carbonyldiimidazole is said to be too slow in reacting with protein functional groups, requiring long reaction times to obtain sufficient modification of the protein.
Still other PEG derivatives have been proposed for attachment to functional groups on amino acids other than the epsilon -NHZ of lysine. Histidine contains a reactive imino moiety, represented structurally as -N(H)-, but many derivatives that react with epsilon -NHZ also react with -N(H)-. Cysteine contains a reactive thiol moiety, represented structurally as -SH, but the PEG derivative maleimide that is reactive with this moiety is subject to hydrolysis.
As can be seen from the small sampling above, considerable effort has gone into developing various PEG derivatives for ai:tachment to, in particular, the -NH2 moiety on the lysine amino acid fraction of various proteins. Many of these derivatives have proven problematic in their synthesis and use. Some form unstable linkages with the protein that are subject to hydrolysis and therefore do not last very long in aqueous environments, such as in the blood stream.
Some form more stable linkages, but are subject to hydrolysis before the linkage is formed, which means that the reactive group on the PEG derivative may be inactivated before the protein can be attached. Some are somewhat toxic anr7. are therefore less suitable for use in vivo. Some are too slow to react to be WO 95!13312 PCT/US94/13013 practically useful. Some result in a loss of protein activity by attaching to sites responsible for the protein's activity. Some are not specific in the sites to which they will attach, which can also result in a loss of desirable activity and in a lack of reproducibility of results.
Summary of the Invention The invention provides water soluble and hydrolytically stable derivatives of polyethylene glycol) ("PEG") polymers and related hydrophilic polymers having one or more active sulfone moieties.
These polymer derivatives with active sulfone moieties are highly selective for coupling with thiol moieties instead of amino moieties on molecules and on surfaces, especially at pHs of about 9 or less. The sulfone moiety, the linkage between the polymer and the sulfone moiety, and the linkage between the thiol moiety and the sulfone moiety are not generally reversible in reducing environments and are stable against hydrolysis for extended periods in aqueous environments at pHs of about 11 or less. Consequently, the physical and chemical characteristics of a wide variety of substances can be modified under demanding aqueous conditions with the active sulfone polymer derivatives.
For example, conditions for modification of biologically active substances can be optimized to preserve a high degree of biological activity.
Pharmaceuticals from aspirin to penicillin can be usefully modified by attachment of active sulfone polymer derivatives if these pharmaceuticals are modified to contain thiol moieties. Large proteins containing cysteine units, which have active thiol moieties, can also be usefully modified. Techniques of recombinant DNA technology ("genetic engineering") can be used to introduce cysteine groups into desired places in a protein. These cysteines can be coupled to active sulfone polymer derivatives to provide ~~76~~~
hydrolytically stab:Le linkages on a variety of proteins that do not normally contain cysteine units.
In accord<~nce with an aspect of the invention, a water soluble hydro:Lytically stable activated polymer comprising at least one active sulfone moiety covalently linked to a polymer selected from the group consisting of poly(alkylene oxide:), poly(oxyethylated polyols), and poly(olefinic alcohols), wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, an activated polyethylene glycol) derivative having the structure:
R-CH2CH2- ( OCH2CH2) n-Y
wherein n equals 5 too 3, 000; Y is -S02-CH2-CH2-X, where X is halogen, and derivatives thereof; and wherein R is selected from the group cons_Lsting of HO-, H3C0-, CH2=CH-S02-, X-CH2 CH2-S02-, and derivatives thereof, or a polyethylene glycol) activating rnoiety other than CH2=CH-S02- or X-CH2-CH2-S02- and derivatives thereof.
In accordance with another aspect of the invention, a hydrolytically stable, biologically active conjugate comprising a biologically active molecule having a reactive thiol moiety and a water-soluble polymer derivative having an active su:~_fone moiety forming a linkage with said thiol moiety, wherein said conjugate being suitable for in vivo administration., In accordance with another aspect of the invention, a hydrolytically stable, biologically active conjugate comprising:
.;
-7a-two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety: and a water-soluble dumbbell polymer derivative having a reactive moiety air each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said react_Lve moieties on said polymer, wherein said active sulfone moiety is an active ethyl sulfone, or i;~ derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, a biolog_Lcally active conjugate comprising an activated water soluble polymer having at least 2() one active sulfone rnoiety that is selective for reaction with thiol moieties,. and at least one other moiety that is selective for react_~on with amino moieties, wherein said at least one active suT_fone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
-~b- 217620 In accordance with another aspect of the invention, a biomatc:rial comprising a surface and at least one water-soluble polymer derivative linked to said surface, said polymer derivai~ive comprising of a polymer selected from the group cons_LSting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) and having at least one active sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from <~ molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, a method for synthesizing a hydrolytically stable water soluble activ<~ted polymer having an active sulfone moiety, the method comprising the step of attaching a linking moiety containing an active sulfone moiety and a different active mo_Lety to a polymer derivative selected from the group cons_Lsting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) having a functional group other than a sulfone moiety and wherein the functional group is selective for other active moiety on said linker moiety.
In accordance with an aspect of the invention, a method for preparing a conjugate of a substance and a water soluble activated polymer selected from the group consisting of poly(alkylene ox~_des), poly(oxyethylated polyols), and poly(olefinic alcohols) having at least one sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or i:~ derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage, said method comprising the steps 217b203 -7c-of reacting the substance with the activated polymer having a active sulfone moiety arid forming a linkage between the substance and the polymer derivative.
In accordance with another aspect of the invention, a method for preparing a conjugate of a bioljogically active molecule and an active derivative of polyi(ethylene glycol), said method comprising the steps of reaching a biologically active molecule having a reactive thio~. moiety with a polyethylene glycol) derivative having an active sulfone moiety and forming a linkage between the thio~. moiety and the active sulfone moiety, wherein said at lea s one active sulfone moiety is an active ethyl sulfone, or i derived from a molecule having a vinyl sulfone group and non-vinyl active group linked to the vinyl sulfone grow for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the inveltion, a h drol ticall stable biolo is Y Y Y a g ally active conjugate that is the reaction product of 1) at least one biolo ically active molecule having the structure W-SH, where'n W- is a biologically active moiety and -SH is a react've thiol moiet y, and 2) a polyethylene glycol) deriv tive activated with one or mare sulfone moieties and havin the structure:
R-CHy-CH2 (OCHzCH2) n-Y
where'In n equals 5 to 3,000 Y is -S _ 02-CH=CHa, and R i s X
CH2-CH -S02-, wherein X is halogen, and wherein said reactive thiol moiety is linked to said at least one active sulfone moietv~.
In accordance with an aspect of the invention, a method for preparing a biologically active conjugate of at least ne biologically active molecule having the structure -~d' W-SH, wherein W- is. a biologically active moiety and -SH is an active thiol moiety, and an activated polyethylene glycol) derivative having at least one active sulfone moiety, the activated polyethylene glycol) derivative havijng the structure R-CH2CHz-(OCH2CH2)"-Y, wherein n equals 5 t ' 3, 000, Y is -SOz-CFi=CH2, and R is X-CHZ-CHZ-S02--, whe ein X is halogen, said method comprising the steps of reacting the biologically active molecule with the activated polyethylene glycol) derivative and forming a linkage betty en the active thiol moiety and the at least one active sulf ne moiety of the polyethylene glycol).
Tn accordance with another aspect of the inve tion, a method of preparing a biologically active conj gate having the structure;
prot in-S-CHz-CHZ-SOZ-CH2-CHz- (OCHZCH2) n-SOz-CHZ-CHZ-S-protein, wher in n equals 5 to 3,000, the method comprising the steps of 1) reactivating at least one protein having an active thio moiety with a sulfone activated polyethylene glycol) deri ative having the structure R-CHZCHZ-(OCH2CH2)n-SOz-CH=CH , wherein R is X-CH2-CHz-SOz, and wherein X is halogen, and 2) forming a linkage between the active thiol moiety of the p otein and the active sulfone moieties of the activated polym, r.
In accordance with another aspect of the inven ion, a method for preparing a biologically active conju ate having the structure H3C0-CHz-CH2- ( OCHzCH2) "-SOZ-CH2-CHZ-S-protein where n n equals 5 to 3,000, the method comprising the steps of 1} reacting a protein having an active Lhidl moiety with an activated poly(et:hylene glycol) derivative having the struct re H3C0-CH2-CHZ- ( OCHZCHZ ) "-SOz-CH=CHZ, wherein the vinyl ulfone moiety is derived from an active ethyl sulfone group, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moiety of the act vated polymer.
In accordance with another aspect of the inn ntion, a pharmaceutical composition comprising a hyd olytically stable, biologically active conjugate, said conjugate comprising of:
a biologically active molecule having a reactive 20 thio moiety or amino moiety; and a water-;soluble polymer derivative having an acti a sulfone moiety forming a covalent linkage with said thio moiety or amino moiety.
Tn accordance with another aspect of the rove tion, a water soluble hydrolytically stable activated poly er comprising at least one active sulfone moiety cova ently linked t:o a polymer selected from the group cons sting of poly;alkylene oxidesy, poly(oxyethylated poly 1s), and poly(;olefinic alcohols), wherein said at least one active sulfone moiety is a vinyl sulfone derived from an actin ethyl sulfon,e group linked to said polymer.
Specific sulfone moieties for the activated polym rs of the invention are those having at least two carbo atoms joined to the sulfone group -SOa- with a react ve site for thiol specific coupling reactions on the secon carbon from the sulfone group.
More specifically, the active sulfone moieties compr'se vinyl sulfone, the active ethyl sulfones, including the h loethyl sulfones, and the thiol-specific active derivatives of these sulfones. The vinyl sulfone moiety can be rep esented stru<aurally as -SOz-CH=CH2; the active ethyl sulfon moiety can be represented structurally as -SOZ-CHZ-CHZ--Z, where Z can be halogen or some other leaving group J
21762p3 -? f-capable of substitution by thiol to form the sulfone and'. thiol linkage ~-SO=-CHI-CHx-s-W, where W represents a bio ogically active molecule, a surface, or some other sub tance. The derivatives of the vinyl and ethyl sul ones can include other substituents~ so long as the wat r solubility and the thiol-specific reactivity of the reactive site on the second carbon are maintained.
The invention includes hydrolytically stable con ugates of substances having thiol moieties with pol er derivative;s having active sulfone moieties.
For example, a wat~~_r soluble sulfone-activated PEG
pol er can be coupled to a biologically active mole ule at a xeac'tive thiol site. The linkage by whic the PEG and the biologically active molecule are 15. coup ed includes a sulfone moiety coupled to a thiol moie y and has the s~xucture PEG-S0,-CH,-CH~-S-W, where W re resents the b.i,ologically active molecule, whether tha ulfone moiety prior to coupling of the PEG was viny sulfonn or an active ethyl sulfone. _' The invention also includes biomaterials comprising a surface having one or more reactive thiol site'~~, and oae or more of the water soluble sulfone-WO 95/13312 PCT/US94l13013 _g_ activated polymers of the invention coupled to the surface by a sulfone and thiol linkage. Biomaterials and other substances can also be coupled to the sulfone activated polymer derivatives through a linkage other than the sulfo:ne and thiol linkage, such as a conventional amino linkage, to leave a more hydrolytically stable activating group, the sulfone moiety, available for subsequent reactions.
The invention includes a method of synthesizing the activated polymers of the invention.
A sulfur containing moiety is bonded directly to a carbon atom of the polymer and then converted to the active sulfone moiety. Alternatively, the sulfone moiety can be prepared by attaching a linking agent that has the sulfone moiety at one terminus to a conventional activated polymer so that the resulting polymer has the sulfone moiety at its terminus.
More specifically, a water soluble polymer having at least one active hydroxyl moiety undergoes a reaction to produce a substituted polymer having a more reactive moiety thereon. The resulting substituted polymer undergoes a reaction to substitute for the more reactive moiety a sulfur-containing moiety having at least two carbon atoms where the sulfur in the sulfur-containing moiety is bonded directly to a carbon atom of the polymer. The sulfur-containing moiety then undergoes reactions to oxidize sulfur, -S-, to sulfone, -SOz-, and to provide a sufficiently reactive site on the second carbon atom of the sulfone containing moiety for formation of linkages with thiol containing moieties.
Still more specifically, the method of synthesizing the activated polymers of the invention comprises reacting polyethylene glycol) with a hydroxyl activating compound to form an ester or with a halogen containing derivative to form a.halogen substituted PE;G. The resulting activated PEG is then.
reacted with mercaptoethanol to substitute the mercaptoethanol radical for the ester moiety or the halide. The sulfur in the mercaptoethanol moiety is oxidized to su=Lfone. The ethanol sulfone is activated by either activating the hydroxyl moiety or substituting t)Ze hydroxyl moiety with a more active moiety such as halogen. The active ethyl sulfone of PEG can then be converted to vinyl sulfone, if desired, by cleaving thc~ activated hydroxyl or other active moiety and introducing the carbon-carbon double bond adj acent the sulfone group -SOZ- .
The :invention also includes a method for preparing a conjugate of a substance with a polymer derivative thaw' has an active sulfone moiety. The method includes the step of forming a linkage between the polymer derivative and the substance, which linkage can be between the sulfone moiety and a thiol moiety.
Thus the invention provides activated polymers that are specific in reactivity, stable in water, stable .in reducing environments, and that form more stable linkages with surfaces and molecules, including biologically active molecules, than previously has been achieved. The activated polymer can be used to modify the characteristics of surfaces and molecules where biocompatibility is of importance.
Because the activated polymer is stable under aqueous conditions and forms stable linkages with thiol moieties, the 'most favorable reaction conditions can be selected for preserving activity of biologically active substances and for optimizing the rate of reaction for polymer coupling.
Detailed DescriQ,tion of the invention The synthetic route used to prepare active sulfones of polyethylene glycol) and related polymers comprises at least four steps in which sulfur is bound to a polymer molecule and then converted through a series of reactions to an active sulfone functional WO 95!13312 217 6 2 0 3 pCTlUS94/13013 group. The starting PEG polymer molecule has at least one hydroxyl moiety, -OH, that is available to participate in chemical reactions and is considered to be an "active" hydroxyl moiety. The PEG molecule can have multiple active hydroxyl moieties available for chemical reaction, as is explained below. These active hydroxyl moieties are in fact relatively nonreactive, and the first step in the synthesis is to prepare a PEG
having a more reactive moiety.
A more reactive moiety typically will be created by one of two routes, hydroxyl activation or substitution. Other methods are available as should be apparent to the skilled artisan, but hydroxyl activation and substitution are the two most often used. In hydroxyl activation, the hydrogen atom -H on the hydroxyl moiety -OH is replaced with a more active group. Typically, an acid or an acid derivative such as an acid halide is reacted with the PEG to form a reactive ester in which the PEG and the acid moiety are linked through the ester linkage. The acid moiety generally is more reactive than the hydroxyl moiety.
Typical esters are the sulfonate, carboxylate, and phosphate esters.
Sulfonyl acid halides that are suitable for use in practicing the invention include methanesulfonyl chloride and p-toluenesulfonyl chloride. Methanesulfonyl chloride is represented structurally as CH3SOZC1 and is also known as mesyl chloride. Methanesulfonyl esters are sometimes referred to as mesylates. Para-toluenesulfonyl chloride is represented structurally as H3CC6H4SOZC1 and is also known as tosyl chloride. Toluenesulfonyl esters are sometimes referred to as tosylates.
In a substitution reaction, the entire -OH
group on the PEG is substituted by a more reactive moiety, typically a halide. For example, thionyl chloride, represented structurally as SOC12, can be 211b203 xea~ted with PEG to form a more reactive chlorine substituted PEG. Substitution of the hydroxyl moiety by another moiety is siometimee referred to in the art as hydroxyl activatior.~. The term "hydroxyl activation" should be interpreted herein to mean substitution as well as estejrification and other methods of hydroxyl activation.
The terms "group," "functional group," "moiety,"
"actjive moiety," "reactive site," and "radical" are somewhat.
eyno ymous in the chemical arts and are used in the art and here'n to refer to distinct, definable portions or unite of a molecule and to unite that perform some function or acts ity and are reactive with other molecules or portions of m lecules. Tn this sense a protein or a protein residue can a considered a molecule or as a functional ,group or mole y when coupled to a polymer.
The term '''PEGS' is used in the art and herein to desc ibe any of several condensation polymers of ethylene glyco having the general formula represented by the strut ure H(OCH,CHs) nOH, which can also be represented as HO-CH CH,- (OCHaCHa) r~-OH. PEG is also known as polyo yethylene, polyethylene oxide, polyglycol, and polye her glycol. PEG can be prepared as copolymers o.f ethyl ne oxide and many other monomers.
Polyethylene glycol) is used in biological applications because it has properties that are highly desire 1e and is generally approved for biological or biotec nical applicat:ione. PEG typically is clear, -11a-colorless, odorles:~; soluble in water, stable to heat, inert to many chemical agents, does not hydrolyze or deteriorate, and ie nontoxic. F~oly(ethylene glycol) is considered to be biocompatible., which is to say that PEG ie capable of coe~ietence with living tissues or organisms without causing harm. More specifically, PEG is nat immunogenic, which is to s;ay that PEG dose not tend to produce an immune response in t~e body. When attached to a moiety having some degi~able function in WO 95/13312 ~ 217 6 2 0 3 p~/US94/13013 the body, the PEG tends to mask the moiety and can reduce or eliminate any immune response so that an organism can tolerate the presence of the moiety.
Accordingly, the sulfone-activated PEGs of the invention should be substantially non-toxic and should not tend substantially to produce an immune response or cause clotting or other undesirable effects.
The second step in the synthesis is to link sulfur directly to a carbon atom in the polymer and in a form that can be converted to an ethyl sulfone or ethyl sulfone derivative having similar reactive properties. "Ethyl" refers to a moiety having an identifiable group of two carbon atoms joined together.
The active sulfone PEG derivative requires that the second carbon atom in the chain away from the sulfone group provide a reactive site far linkages of thiol moieties with t:he sulfone. This result can be achieved by reacting the active moiety produced in the first step mentioned .above, which typically will be the ester or halide substituted PEG, in a substitution reaction with an alcohol that also contains a reactive thiol moiety attached to an ethyl group, a thioethanol moiety. The thiol moiety is oxidized to sulfone and the second carbon away from the sulfone on the ethyl group is converted to a reactive site. , Compownds containing thiol moieties, -SH, are organic compounds that resemble alcohols, which contain the hydroxyl moiety -OH, except that in thiols, the oxygen of at least one hydroxyl moiety is replaced by sulfur. The activating moiety on the PEG derivative from the first :reaction, which typically is either halide or the acid moiety of an ester, is cleaved from the polymer and is replaced by the alcohol radical of the thioethanol compound. The sulfur in the thiol moiety of the alcohol is linked directly to a carbon on the polymer.
WO 95/13312 217 6 2 0 3 1'CTIUS94/13013 The alcohol should be one that provides a thioethanol moiety for attachment directly to the carbon of the polymer chain, or that can easily be converted to a thioethanol moiety or substituted moiety of similar reactive properties. An example of such an alcohol is mercaptoethanol, which is represented structurally as HSCHZCHZOH and is sometimes also called thioethanol.
In the third step of the synthesis, an oxidizing agent is used to convert the sulfur that is attached to the carbon to the sulfone group, -SO2.
There are many such oxidizing agents, including hydrogen peroxide and sodium perborate. A catalyst, such as tungst:ic acid, can be useful. However, the sulfone that i;~ formed is not in a form active for thiol-selective reactions and it is necessary to remove the relatively unreactive hydroxyl moiety of the alcohol that was added in the substitution reaction of the second step.
In tine fourth step, the hydroxyl moiety of the alcohol that was added in the second step is converted to a more reactive form, either through activation of 'the hydroxyl group or through substitution of the hydroxyl group with a more reactive group, similar to the first step in the reaction sequence. Substitution typically is with halide to form a haloethyl sulfone or a derivative thereof having a reactive site on the second carbon removed from the sulfone moiety. Typically, the second carbon on the ethyl group will be activated by a chloride or bromide halogen. Hydroxyl activation should provide a site of similar reactivity, such as the sulfonate ester.
Suitable reactants are the acids, acid halides, and others previously mentioned in connection with the first step in the reaction, especially thionyl chloride for substitution of the hydroxyl group with the chlorine atom.
WO 95/13312 2 ~ ~ 6 2 ~ PCTIUS94/13013 The resulting polymeric activated ethyl sulfone is stable, isolatable, and suitable for thiol-selective coupling reactions. As shown in the examples, PEG chloroethyl sulfone is stable in water at a pH of about 7 or less, but nevertheless can be used to advantage for thiol-selective coupling reactions at conditions of basic pH up to at least about pH 9.
In the thiol coupling reaction, it is possible that the thiol moiety displaces chloride, as in the following reaction:
PEG-SOz-CHZ-CHZ-C1 + W-S-H -j PEG-S02-CHz-CHZ-S-W, where W represents the moiety to which the thiol moiety SH is linked and can be a biologically active molecule, a surface, or some other substance. However, and while not wishing to be bound by theory, it is believed, based on the observable reaction kinetics as shown in Example 3, that the chloroethyl and other activated ethyl sulfones and reactive derivatives are converted to PEG vinyl sulfone, and that it is the PEG vinyl sulfone or derivative thereof that is actually linked to the thiol moiety. Nevertheless, the resulting sulfone and thiol linkage is not distinguishable, whether from active PEG ethyl sulfone or from PEG vinyl sulfone, and so the active ethyl sulfone can be used at pHs above 7 for linking to thiol groups.
PEG vinyl sulfone is also stable and isolatable and can form thiol-selective, hydrolytically stable linkages, typically in much less time than the haloethyl sulfone or other activated ethyl sulfone, as explained further below.
In a fifth step that can be added to the synthesis, the activated ethyl sulfone is reacted with any of a variety of bases, such as sodium hydroxide or triethylamine, to form PEG vinyl sulfone or one of its active derivatives for use in thiol-selective coupling reactions.
WO 95!13312 21 ~ 6 2 0 3 PCT/I1S94/13013 As shown in the examples below, especially Example 3, PEG vinyl sulfone reacts quickly with thiol moieties and is stable against hydrolysis in water of pH less than about 11 for at least several days. The reaction can be. represented as follows:
PEG-S02-CH=CH2 + W-S-H --~ PEG-S02-CHz-CHZ-S-W.
The thiol moiety is said to add "across the double bond." The W-S moiety adds to the terminal CHz of the double bond, which is the second carbon from the sulfone group 502. The hydrogen H adds to the CH of the double bond. However, at a pH of above about 9, selectivity of the sulfone moiety for thiol is diminished and the sulfone moiety becomes somewhat more reactive with amino groups.
Alternatively to the above synthesis, the sulfone-activated PEG derivatives can be prepared by attaching a linking agent having a sulfone moiety to a PEG activated with a different functional group. For example, an amino activated PEG, PEG-NH2, is reacted under favorable' conditions o:E pH of about 9 or less with a small molecule that has a succinimidyl active ester moiety NF~S-02C- at one terminus and a sulfone moiety, vinyl :~ulfone -SOZ-CH=CH2, at the other terminus. The amino activated PEG forms a stable linkage with the succinimidyl ester. The resulting PEG
is activated with the vinyl sulfone moiety at the terminus and i:~ hydrolytically stable. The reaction and the resulting vinyl sulfone activated PEG are represented stx-ucturally as follows:
PEG-NHz + NHS-OzC-CH2-C:Eiz-S02-CH=CHZ
PEG-NH-OC-CH2-CHz-SOz-CH=CH2.
A similar activated PEG could be achieved by reacting an amine-activated PEG such as succinimidyl active ester PE:G, PEG-COZ-NHS, with a small molecule that has an amine moiety at one terminus and a vinyl sulfone moiety at the other terminus. The succinimidyl WO 95/13312 21 l 6 2 ~ 3 PCTIUS94113013 ester forms a stable linkage with the amine moiety as follows : PEG-CO2-NHS + NHZ-CHZ-CH2-S02-CH=CHZ -~
PEG- CO-NH- CH2-CHZ-SOZ- CH=CHZ .
The active PEG sulfones of the invention can be of any molecular weight and can be linear or branched with hundreds of arms. The PEG can be substituted or unsubstituted so long as at least one reactive site is available for substitution with the sulfone moieties. PEG typically has average molecular weights of from 200 to 100,000 and its biological properties can vary with molecular weight and depending on the degree of branching and substitution, so not all of these derivatives may be useful for biological or biotechnical applications. For most biological and biotechnical applications, substantially linear, straight-chain PEG vinyl sulfone or bis vinyl sulfone or activated ethyl sulfone will be used, substantially unsubstituted except for the vinyl sulfone or ethyl sulfone moieties and, where desired, other additional functional groups. For many biological and biotechnical applications, the substituents would typically be unreactive groups such as hydrogen H- and methyl CH3- ( "m-PEG" ) .
The PEG can have more than one vinyl sulfone or precursor moiety attached or the PEG can be capped on one end with a relatively nonreactive moiety such as the methyl radical, -CH3. The capped form can be useful, for example, if it is desirable simply to attach the polymer chains at various thiol sites along a protein chain. Attachment of PEG molecules to a biologically active molecule such as a protein or other pharmaceutical or to a surface is sometimes referred to as "PEGylation."
A linear PEG with active hydroxyls at each end can be activated at each end with vinyl sulfone or its precursor or derivatives of similar reactivity to become bifunctional. The bifunctional structure, PEG
2~ ~6~03 bis vinyl sulfonE~, for example, is sometimes referred to as a dumbbell structure and can be used, for example, as a linker or spacer to attach a biologically active molecule t:o a suxface or to attach more than one such biologically active molecule to the PEG molecule.
The stability of the sulfone moiety against hydrolysis ma es it particu:lariy useful fox bi-functional or he exobifunc~ion~~l applications.
Another application for PEG vinyl sulfone and it precursor is dendritic activated PEG in which mu tiple arms of PEG are attached to a central core st ucture. l7end:ritic PEG structures can be highly br nched and are commonly known as ~~star~~ molecules.
Star molecules era generally described in Merrill U.S.
Patient No. 5,171,264. The sulfone moieties can be used to pro~ride an active, functional group on the end of the PEG
chain extending from the core and as a linker for joining a functional group to the star molecule arms.
PEG vinyl sulfone and its precursors and der natives can ;be used for attachment directly to sur aces and mohecules having a thiol moiety. However, mor typically a heterobifunctional PEG derivative hav'ng a eulfone moiety on one terminus and a different fun tional moiety on the opposite terminus group will be attached by t:he different moiety to a surface or mole ule. When substituted with one of the other acts a moieties, the heterobifunctional PEG dumbbell stru ture.can be used, fox example, to carry a protein or o her biologically active molecule by sulfone link ges on one ,and and by another linkage on the other end, such as an .amine linkage,~to produce a molecule havi g two different activities. A heterobifunctivnal PEG awing a sul:fone moiety on one end and an amine spec fic moiety on the other end could be attached to both cysteine and lysine fractions of proteins. A
stable amine linkage can be achieved and then the hydrolytically stable unreacted sulfone moiety is available for subsequent thiol-specific reactions as desired.
Other aci~ive groups for heterobifunctional sulfone-activated PEGS can be selected from among a wide variety of compounds. For biological and biotechnical applications, the substituents would typically be selected from reactive moieties typically used in PEG chemistry to activate PEG such as the aldehydes, l~rifluoroethylsulfonate, which is also sometimes called tresylate, n-hydroxylsuccinimide ester, cyanuric chloride, cyanuric fluoride, aryl azide, succinate, the p-diazo benzyl group, the 3-(p-diazophenyloxy)-2-hydroxy propyloxy group, and others.
Examples of active moieties other than sulfone are shown .in Davis et al. U.S. Patent No.
4,179,337; Lee et <~l. U.S. Patent Nos. 4,296,097 and 4,430,260; Iwasaki at al. 4,670,417; Katre et al. U.S.
Patent Nos. 4,766,:106; 4,917,888; and 4,931,544;
Nakagawa et al. U.S. Patent No. 4,791,192; Nitecki et al. U.S. Patent No. 4,902,502 and 5,089,261; Saifer U.S. Patent No. 5,080,891; 2alipsky U.S. Patent No.
5,122,614; Shadle et al. U.S. Patent No. 5,153,265;
Rhee et al. U.S. Patent No. 5,162,430; published European Patent Application Publication No. 0 247 860; and published WO 8700056, WO 9004606, WO 9004384, WO 9107190, WO 9204384, WO 9213095 and WO 9216555.
It should be apparent to the skilled artisan that the dumbbell strucl~ures discussed above could be used to carry a wide variet=y of substituents and combinations of substituents. Pharmaceuticals such as aspirin, vitamins, penicillin, and others too numerous to mention; polypeptides or proteins and protein fragments of various functionalities and molecular v weights; cells of various types; surfaces for biomaterials, almøst any eubstanc~e could be modified. As used herein, the term "protein" sho~;~,ld be understood to include peptides and pol~peptides, which are polymers of amino acids. The term "bi material" mean's a material, typically synthetic and som times made of plastic, that is suitable for implanting in living body to repair damaged or diseased parts. An exa 1e of a biomat.erial is artificial blood vessels.
One straight chain PEG derivative of the invention for iological and biotechnical applications has the basic stru tune R-CHaCH'- ~;OCHaCHs) "-Y. The PEG monomer OCHzCH~
pref rably is substantially unsubstituted and unbranched alon the polymer backbone. The subscript "n" can equal from about 5 to 3,000. A more typical range is from about 5 to 2,200, which corresponds to a molecular weight of from abou 220 to 100,000. Still more typical is a range of from about 34 to 1,100, which corresponds to a molecular weight range of from about 1,500 to 50,000. Most applications will be ac omplished with molecular weights in the neighborhood of 2, 00 to 5;000, which corresponds to a value of n of from about 45 to 110.
In the above structure, Y represents -SOa- CH=CHI
or -S a-CHa-CHz-X where X is a halogen. R repregenta a group that ay be the same or different from Y. R can be HO-, H3 C0-, CHz=CH-SO,-, C1-CHa-CHa-SOz-, or a polymer activating _. ._ . ,~
-__ _ ..~~ . : ~ .
-19a-group other than C;Ha=CH-Saa-,C1-CHs-CHI-SOz-, such as is referred to with respect to the above patents and published patent applications.
The act:_ve polymer derivatives are water soluble and.hydrolyticall;r stable and produce water soluble and hydxolytically stable linkages with thiol groups. The derivatives are considered infinitely soluble in water or as approaching infinite solubility and can enable atherwiee insoluable molecules to page into solution when conjugated with. the derivative.
r _:.,., . . w 217 b203 WO 95113312 PCTlUS94113013 Hydrc>lytic stability of the derivatives means that the linkage between the polymer and the sulfone moiety is stable in water and that the vinyl sulfone moiety does not: react with water at a pH of less than about 11 for arL extended period of time of at least several days, and potentially indefinitely, as shown in Example 3 below. The activated ethyl sulfone can be converted to the vinyl sulfone at conditions of basic pH, with the same resulting stability. Hydrolytic stability of the thiol linkage means that conjugates of the activated polymer and a substance having a thiol moiety are stable at the sulfone-thiol linkage for an extended period of time in aqueous environments at a pH
of below about 11. Most proteins could be expected to lose their activity at a caustic pH of 11 or higher, so it should be apparent to the skilled artisan that many applications for the active sulfone PEG derivatives will be at pHs of less than 11, regardless of the stability of the sulfone moiety at higher pH.
To be useful for modification of proteins and other substance=s, it is only necessary that the sulfone be stable for a period of time sufficient to permit the sulfone to react with a reactive thiol moiety on the protein or other substance. The rate of reaction of the sulfone moiety with thiol can vary with pH, as shown in Examp:Le 2 below, from about 2 minutes to 30 minutes, which is much faster than the rate of hydrolysis, if any. Vinyl sulfone could be expected to react with thiol over a much broader range of reaction times since it is stable for long periods of time.
Also, as shown in Example 3 below, at conditions of basic pH chloroethyl sulfone is not hydrolyzed, but is converted to vinyl sulfone, which remains stable for several days a:nd is even more reactive toward thiol groups. Accordingly, for the purpose of modifying the characteristics of substances, the active ethyl sulfones can also be considered to be hydrolytically stable for an extended period of time over a broad pH
range.
Other water soluble polymers than PEG are believed to be suitable for similar modification and activation with an active sulfone moiety. These other polymers include polyvinyl alcohol) ("PVA"); other poly(alkylene oxides) such as polypropylene glycol) ("PPG") and the: like; and poly(oxyethylated polyols) such as poly(o~:yethylated glycerol), poly(oxyethylated sorbitol), and poly(oxyethylated glucose), and the like. The polymers can be homopolymers or random or block copolymers and terpolymers based on the monomers of the above polymers, straight chain or branched, or substituted or unsubstituted similar to PEG, but having at least one a<aive site available for reaction to form the sulfone mo~~ety.
The i:ollowin.g Example 1 shows the synthesis, isolation, and characterization of polyethylene glycol) chloroethyl sulfone followed by the preparation of polyethylene glycol) vinyl sulfone from the chloroethyl sulfone. Preparation of other polymeric sulfones having a reactive site on the second carbon from the sulfone group is similar and the steps for doing so should be apparent to the skilled artisan based on Examp:Le 1 below and the polymers listed above.
Example 1: Synthesis The .reaction steps can be illustrated structurally as follows:
( 1 ) PEG-OH + CH3SOZC1 ~ PEG-OSOzCH3 (2) PEG-OSO.,CH3 + HSCHZCH20H ~ PEG-SCHZCHZOH
(3) PEG-SCH.;CHzOH + H202 ~ PEG-SOZCHZCH20H
(4) PEG-SOZC:HzCH20H + SOC12 ~ PEG-SOZCHzCH2C1 ( 5 ) PEG-SOz- CHZCHzCl + NaOH ~ PEG-SOz-CH=CHz + HC1 Each of the above reactions is described in detail below:
Reaction 1. Reaction 1 represents the preparation of the methane sulfonyl ester of polyethylene glycol), which can also be referred to as the methanesulfonate or mesylate of polyethylene glycol). The tosylate and the halides can be prepared by similar procedures, which are believed to be apparent to the skilled artisan.
To prepare the mesylate, twenty-five grams of PEG of molecular weight 3400 was dried by azeotropic distillation in 150 ml of toluene. Approximately half of the toluene was distilled off in drying the PEG.
Forty ml of dry dichloromethane was added to the toluene and PEG solution, followed by cooling in an ice bath. To the cooled solution was added 1.230 ml of distilled methanesulfonyl chloride, which is an equivalent weight of 1.06 with respect to PEG hydroxyl groups, and 2.664 ml of dry triethylamine, which is an equivalent weight of 1.3 with respect to PEG hydroxyl groups. "Equivalent weight" as used above can be thought of as "combining weight" and refers to the weight of a compound that will react with an equivalent weight of PEG hydroxyl groups.
The reaction was permitted to sit overnight during which time it warmed to room temperature.
Triethylammonium hydrochloride precipitated and the precipitate was removed by filtration. Thereafter, the volume was reduced by rotary evaporation to 20 ml. The mesylate was precipitated by addition to 100 ml of cold dry ethyl ether. Nuclear magnetic resonance (NMR) analysis showed 1000 conversion of hydroxyl groups to mesylate groups.
Reaction 2. Reaction 2 represents the formation of polyethylene glycol) mercaptoethanol by reaction of the mesylate with mercaptoethanol. The reaction causes the methanesulfonate radical to be displaced from the PEG. The sulfur in the mercaptoethanol radical is attached directly to the carbon in the carbon-carbon backbone of the PEG.
WO 95113312 ~ 17 6 2 0 3 PCT/US94/13013 Twenty grams of the mesylate from reaction 1 was dissolved un 150 ml of distilled water. The solution of me;~ylate a.nd water was cooled by immersion in an ice bath., To the cooled solution was added 2.366 ml of mercaptoethanol, which is 3 equivalent weights with respect to PEG :hydroxyl groups. Also added was 16.86 ml of 2N NaOH base. The reaction was refluxed for 3 hours, which means that the vapors rising from the reaction were continuously condensed and allowed to flow back into the reaction.
The polyethylene glycol) mercaptoethanol product was ext:racted three times with dichloromethane using approximately 25 ml of dichloromethane each time.
The organic fractions were collected and dried over anhydrous magnesium sulfate. The volume was reduced to ml and the product was precipitated by addition to 150 ml of cold dry ether.
NMR analysis in d6-DMSO dimethyl sulfoxide gave the following peaks for PEG-SCH2CH20H: 2.57 ppm, 20 triplet, -CH2-~~-; 2.65 ppm, triplet, -S-CH2-; 3.5 ppm, backbone singlc~t; and 4.76 ppm, triplet, -OH. The hydroxyl peak at 4.76 ppm indicated 81% substitution.
However, the 2.65 ppm peak for -S-CH2- indicated 100%
substitution. It has been observed that hydroxyl peaks frequently give low figures on percent substitution, and so the 2.65 ppm peak for -S-CH2- is considered to be more reliable .and to confirm 100% substitution.
Reaction 3. Reaction 3 represents peroxide oxidation of t:he polyethylene glycol) mercaptoethanol product to convert the sulfur, S, to sulfone, 502. PEG
ethanol sulfone is produced.
Twenty grams of PEG-SCH2CH20H was dissolved in 30 ml of 0.123.M tungstic acid solution and cooled in an ice bath. The tungstic acid. solution was prepared by dissolving the acid in sodium hydroxide solution of pH
11.5 and then adjusting the pH to 5.6 with glacial acetic acid. Twenty ml of distilled water and 2.876 ml of 30% hydrogen. peroxide, which has an equivalent weight of 2.5 with respect to hydroxyl groups, was added to the solution of tungstic acid and polyethylene glycol) mercaptoethanol and the.reaction was permitted to warm overnight to room temperature.
The oxidized product was extracted three times with dichloromethane using 25 ml of dichloromethane each time. The collected organic fractions were washed with dilute aqueous sodium bicarbonate and dried with anhydrous magnesium sulfate.
The volume was reduced to 20 ml. The PEG ethanol sulfone product was precipitated by addition to cold dry ethyl ether.
NMR analysis in d6-DMSO dimethyl sulfoxide gave the following peaks for PEG-S02CHZCHzOH: 3.25 ppm, triplet, -CH2-SOZ-; 3.37 ppm, triplet, -SOZ-CHZ-; 3.50 ppm, backbone; 3.77 ppm, triplet, -CHzOH; 5.04 ppm, triplet, -OH. The hydroxyl peak at 5.04 ppm indicated 85a substitution. However, the peak at 3.37 ppm for -SOZ-CHz- indicated 1000 substitution and is considered to be more reliable.
Reaction 4. Reaction 4 represents the final step in synthesis, isolation, and characterization of polyethylene glycol) chloroethyl sulfone.
To synthesize the product, twenty grams of PEG-S02CHZCHZOH poly (ethylene glycol) ethanol sulfone was dissolved in 100 ml of freshly distilled thionyl chloride and the solution was refluxed overnight. The thionyl chloride had been distilled over quinoline.
Excess thionyl chloride was removed by distillation.
Fifty milliliters of toluene and 50 ml of dichloromethane were added and removed by distillation.
To isolate the product, the PEG chloroethyl sulfone was dissolved in 20 ml of dichloromethane and precipitated by addition to 100 ml of cold dry ethyl ether. The precipitate was recrystallized from 50 ml of ethyl acetate to isolate the product.
WO 95!13312 PCT/US94113013 Nucle:ar magnetic resonance was used to characterize the product. NMR analysis of PEG-SOZCHZCHzCl in d6-DMSO dimethyl sulfoxide gave the following peaky>: 3.50 ppm, backbone; 3.64 ppm, triplet, -CHZSOz-; 3.80 ppm, 'triplet, -SOz-CH2-. A small hydroxyl impurity triplet appeared at 3.94 ppm.
Calculation of the percentage substitution was difficult for t=his spectrum because of the proximity of the important peaks to the very large backbone peak.
React:ioa 5. Reaction 5 represents conversion of polyethylene glycol) chloroethyl sulfone from reaction step ~: to polyethylene glycol) vinyl sulfone and isolation and characterization of the vinyl sulfone product.
The PEG vinyl sulfone was readily prepared by dissolving solid PEG chloroethyl sulfone in dichloromethane solvent followed by addition of two equivalents of NaOH base. The solution was filtered to remove the base and the solvent was evaporated to isolate the final product PEG-SOZ-CH=CH2 PEG vinyl sul f one .
The T?EG vinyl sulfone was characterized by NMR analysis in d6-DMSO dimethyl sulfoxide. NMR
analysis showed the following peaks: 3.50 ppm, backbone; 3.73 ppm, triplet, -CH2-SOZ-; 6.21 ppm, triplet, =CH2; 6.97 ppm, doublet of doublets, -S02-CH-.
The 6.97 ppm pe=ak for -SOZ-CH- indicated 84%
substitution. The 6.21 ppm peak for =CH2 indicated 940 substitution. Titration with mercaptoethanol and 2,2'-dithiodip;rridine indicated 95o substitution.
Example 2: Thiol-selective Reactivity Example 2 shows that PEG vinyl sulfone and its precursor l?EG chloroethyl sulfone are significantly more reactive with thial groups (-SH) than with amino groups (-NHZ) or imino groups (-NH-). Compounds containing thiol groups are organic compounds that resemble alcohols, which contain the hydroxyl group WO 95!13312 217 6 2 0 3 pCT/US94/13013 -OH, except that in thiols, the oxygen of the hydroxyl group is replaced by sulfur. Thiols sometimes are also called sulfhydryls or mercaptans. PEG vinyl sulfone contains the vinyl sulfone group -S02-CH=CHz. PEG
chloroethyl sulfone contains the chloroethyl sulfone group -SOZCHZCH2C1.
Selectivity for thiols is important in protein modification because it means that cysteine units (containing -SH) will be modified in preference to lysine units (containing -NHZ) and histidine units (containing -NH-). The selectivity of PEG vinyl sulfone for thiols means that PEG can be selectively attached to cysteine units, thus preserving protein activity for specific proteins and controlling the number of PEG molecules attached to the protein.
The relative reactivity of PEG vinyl sulfone with thiol and amino groups was determined by measuring the rates of reaction of PEG vinyl sulfone with N-a-acetyl lysine methyl ester and with mercaptoethanol. N-a-acetyl lysine methyl ester is a lysine model containing an amino group and is abbreviated Lys-NH2. Mercaptoethanol serves as a cysteine model containing a thiol group and is abbreviated Cys-SH. Relative reactivity of PEG
chloroethyl sulfone was similarly determined. This molecule may serve as a "protected" form of the vinyl sulfone since it is stable in acid but converts to PEG
vinyl sulfone upon addition of base.
Reactivity for PEG vinyl sulfone and for the PEG chloroethyl sulfone precursor was investigated at pH 8.0, pH 9.0, and at pH 9.5. Buffers for controlling the pH were 0.1 M phosphate at pH 8.0 and 0.1 M borate at pH 9.0 and at pH 9.5. For measurement of mercaptoethanol reactivity, 5 mM ethylenediamine tetraacetic acid (EDTA) was added to both buffers to retard conversion of thiol to disulfide.
aW0 95113312 217 6 2 0 3 F'CTIUS94113013 For reaction of the PEG derivatives of the invention with Lys-NH2, a 3 mM solution of the PEG
derivative was added under stirring to a 0.3 mM Lys-NH2 solution in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by addition of fluorescamine to the reaction solution to produce a fluorescent derivative from reaction with remaining amino groups. The monitoring step was performed by adding 50 ~L of reaction mixture to 1.950 mL of phosphate buffer of ph 8.0 followed by adding 1.0 mL of fluorescamine solution under vigorous stirring.
The fluorescamine solution was 0.3 mg fluorescamine per ml of acetone.
Fluorescence was measured 10 minutes after mixing. Excitation was shown at wavelength 390 nm.
Light emission occurred at 475 nm. No reaction was observed in 24 hours for either PEG vinyl sulfone or PEG chloroethyl sulfone at pH 8Ø At pH 9.5 the reaction was slow, but all amino groups were reacted after several days.
For reaction of the PEG vinyl sulfone and PEG
chloroethyl sulfone precursor with Cys-SH, a 2 mM
solution of the PEG derivative was added to a 0.2 mM
solution of Cys-SH in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by adding 4-dithiopyridine to the reaction solution. The 4-dithiopyridine compound reacts with Cys-SH to produce 4-th.iopyridone, which absorbs ultraviolet light.
The monitoring step was performed by adding 50~.L of reaction mixture to 0.950 mL of 0.1 M phosphate buffer at pH 8.0 and containing 5 mM EDTA, followed by adding one mL of 2 mM ~4-dithiopyridine in the same buffer.
Absorbance of 4-thiopyridone was measured at 324 nm. Both F~EG vinyl sulfone and PEG chloroethyl sulfone showed reactivity toward Cys-SH, with PEG vinyl WO 95!13312 21 l b 2 0 3 PCTIUS94I13013 -28_ sulfone showing greater reactivity. At pH 9.0 the reaction is over within two minutes using the vinyl sulfone and within 15 minutes using the chloroethyl sulfone. However, these reactions were too fast for determination of accurate rate constants. At pH 8.0 the reactions were slower, but still complete in one hour for vinyl sulfone and in three hours for the chloroethyl sulfone. The conversion of chloroethyl sulfone to vinyl sulfone is significantly slower than the reaction of vinyl sulfone with Cys-SH. Thus the rate of reaction for chloroethyl sulfone with Cys-SH
appears to be dependent on the rate of conversion of chloroethyl sulfone to vinyl sulfone. Nevertheless, these reaction rates were still much faster than for the reaction with Lys-NH2.
The above kinetic studies demonstrate the following points. PEG vinyl sulfone is much more reactive with thiol groups than with amino groups, indicating that attachment of PEG vinyl sulfone to a protein containing both cysteine and lysine groups proceeds primarily by reaction with cysteine. Since reactivity with amino groups is similar to imino groups, then reactivity of histidine subunits will also be much lower than reactivity with cysteine subunits.
Also, selectivity toward thiol groups is accentuated at lower pH values for PEG chloroethyl sulfone and PEG
vinyl sulfone, although the reactions of PEG
chloroethyl sulfone are somewhat slower.
The utility of many PEG derivatives is limited because they react rapidly with water, thus interfering with attempts to attach the derivative to molecules and surfaces under aqueous conditions. The following Example 3 shows that PEG vinyl sulfone and PEG chloroethyl sulfone are stable in water.
Example 3: Hydrolytic Stability PEG vinyl sulfone was dissolved in heavy water, D20 deuterium oxide, and monitored by NMR.
WO 95113312 217 6 2 0 3 p~'~s94113013 Reaction did not occur. A solution of PEG chloroethyl sulfone produced PEG vinyl sulfone in heavy water that was buffered with borate to pH 9Ø Monitoring with NMR showed that PEG vinyl sulfone, once produced, was stable for three days in heavy water.
PEG chloroethyl sulfone is stable in water until solution: becomes basic, at which time it is converted intc> vinyl sulfone. Conversion to vinyl sulfone has beam demonstrated by dissolving PEG
chloroethyl sulfone in water at pH 7 and in borate buffer at pH 9. The PEG derivative is extracted into methylene chloride. Removal of methylene chloride, followed by NMR analysis showed that PEG chloroethyl sulfone is stable at a neutral pH of 7.0, and reacts with base to produce PEG vinyl sulfone.
Vinyl sulfone is stable for several days in water, even at basic pH. Extensive hydrolytic stability and thiol-specific reactivity of PEG vinyl sulfone means that PEG vinyl sulfone and its precursor are useful for modification of molecules and surfaces under aqueous conditions, as shown in the following Example 4.
Example 4~ Protein Con-iuQation Protein modification was demonstrated by attachment of the PEG derivative to bovine serum albumin (BSA) by two different methods. BSA is a protein. Native unmodified BSA contains cystine groups which do not contain thiol groups. The cystine units are tied up as disulfide linkages, S-S.
In the first method, m-PEG vinyl sulfone of molecular weight 5,000 was reacted with unmodified BSA
for 24 hours in a 0.1 M borate buffer at pH 9.5 at room temperature. The solution contained 1 mg of BSA and 1 mg of m-PEG vinyl sulfone of molecular weight 5,000 per ml of solution. The results from the Example 2 model compounds had indicated that lysine subunits~ (and possibly hist~idine subunits) would be modified under WO 95/13312 21 ~ 6 2 (~ 3 these relatively basic conditions and in the absence of free thiol groups available for reaction.
Attachment to lysine subunits was demonstrated in two ways. First, size exclusion chromatography showed that the molecular weight of the protein had increased by approximately 50a, thus indicating attachment of approximately 10 PEGS to the protein. Second, fluorescamine analysis showed that the number of lysine groups in the BSA molecule had been reduced by approximately ten.
In the second method, the BSA was treated with tributylphosphine to reduce the disulfide S-S
bonds to thiol groups, -SH, which are available for reaction. The modified BSA was then treated with PEG
chloroethyl sulfone at pH 8.0 in a 0.1 M phosphate buffer at room temperature for 1 hour. The solution contained 1 mg of modified BSA and 1 mg of m-PEG
chloroethyl sulfone of molecular weight 5,000 per ml of solution. The results showed that lysine groups were unreactive under these conditions. However, thiol groups were reactive.
Attachment of the PEG to the protein was demonstrated by size exclusion chromatography, which showed an increase in the molecular weight of the protein by about 250. Fluorescamine analysis indicated no change in number of lysine subunits in the protein, thus confirming that PEG attachment did not take place on lysine subunits. Substitution on thiol groups was thereby confirmed.
The invention claimed herein has been described with respect to particular exemplified embodiments. However, the foregoing description is not intended to limit the invention to the exemplified embodiments, and the skilled artisan should recognize that variations can be made within the spirit and scope of the invention as described in the foregoing specification. On the contrary, the invention includes all alternatives, modifications, and equivalents that may be included within the true spirit and scope of the invention as defined by the appended claims.
WO 95!13312 PCTIUS94/13013 _S_ is said to exhibit an undesirable toxicity and to be non-specific for react: ion with particular functional groups on a protein. The PEG-cyanuric chloride derivative may therefore have undesirable side effects and may reduce protein activity because it attaches to a number of different types of amino acids at various reactive sites. PEG-phenylcarbonate is said to produce toxic hydrophobic phenol residues that have affinity for proteins. PEG act=ivated with carbonyldiimidazole is said to be too slow in reacting with protein functional groups, requiring long reaction times to obtain sufficient modification of the protein.
Still other PEG derivatives have been proposed for attachment to functional groups on amino acids other than the epsilon -NHZ of lysine. Histidine contains a reactive imino moiety, represented structurally as -N(H)-, but many derivatives that react with epsilon -NHZ also react with -N(H)-. Cysteine contains a reactive thiol moiety, represented structurally as -SH, but the PEG derivative maleimide that is reactive with this moiety is subject to hydrolysis.
As can be seen from the small sampling above, considerable effort has gone into developing various PEG derivatives for ai:tachment to, in particular, the -NH2 moiety on the lysine amino acid fraction of various proteins. Many of these derivatives have proven problematic in their synthesis and use. Some form unstable linkages with the protein that are subject to hydrolysis and therefore do not last very long in aqueous environments, such as in the blood stream.
Some form more stable linkages, but are subject to hydrolysis before the linkage is formed, which means that the reactive group on the PEG derivative may be inactivated before the protein can be attached. Some are somewhat toxic anr7. are therefore less suitable for use in vivo. Some are too slow to react to be WO 95!13312 PCT/US94/13013 practically useful. Some result in a loss of protein activity by attaching to sites responsible for the protein's activity. Some are not specific in the sites to which they will attach, which can also result in a loss of desirable activity and in a lack of reproducibility of results.
Summary of the Invention The invention provides water soluble and hydrolytically stable derivatives of polyethylene glycol) ("PEG") polymers and related hydrophilic polymers having one or more active sulfone moieties.
These polymer derivatives with active sulfone moieties are highly selective for coupling with thiol moieties instead of amino moieties on molecules and on surfaces, especially at pHs of about 9 or less. The sulfone moiety, the linkage between the polymer and the sulfone moiety, and the linkage between the thiol moiety and the sulfone moiety are not generally reversible in reducing environments and are stable against hydrolysis for extended periods in aqueous environments at pHs of about 11 or less. Consequently, the physical and chemical characteristics of a wide variety of substances can be modified under demanding aqueous conditions with the active sulfone polymer derivatives.
For example, conditions for modification of biologically active substances can be optimized to preserve a high degree of biological activity.
Pharmaceuticals from aspirin to penicillin can be usefully modified by attachment of active sulfone polymer derivatives if these pharmaceuticals are modified to contain thiol moieties. Large proteins containing cysteine units, which have active thiol moieties, can also be usefully modified. Techniques of recombinant DNA technology ("genetic engineering") can be used to introduce cysteine groups into desired places in a protein. These cysteines can be coupled to active sulfone polymer derivatives to provide ~~76~~~
hydrolytically stab:Le linkages on a variety of proteins that do not normally contain cysteine units.
In accord<~nce with an aspect of the invention, a water soluble hydro:Lytically stable activated polymer comprising at least one active sulfone moiety covalently linked to a polymer selected from the group consisting of poly(alkylene oxide:), poly(oxyethylated polyols), and poly(olefinic alcohols), wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, an activated polyethylene glycol) derivative having the structure:
R-CH2CH2- ( OCH2CH2) n-Y
wherein n equals 5 too 3, 000; Y is -S02-CH2-CH2-X, where X is halogen, and derivatives thereof; and wherein R is selected from the group cons_Lsting of HO-, H3C0-, CH2=CH-S02-, X-CH2 CH2-S02-, and derivatives thereof, or a polyethylene glycol) activating rnoiety other than CH2=CH-S02- or X-CH2-CH2-S02- and derivatives thereof.
In accordance with another aspect of the invention, a hydrolytically stable, biologically active conjugate comprising a biologically active molecule having a reactive thiol moiety and a water-soluble polymer derivative having an active su:~_fone moiety forming a linkage with said thiol moiety, wherein said conjugate being suitable for in vivo administration., In accordance with another aspect of the invention, a hydrolytically stable, biologically active conjugate comprising:
.;
-7a-two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety: and a water-soluble dumbbell polymer derivative having a reactive moiety air each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said react_Lve moieties on said polymer, wherein said active sulfone moiety is an active ethyl sulfone, or i;~ derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, a biolog_Lcally active conjugate comprising an activated water soluble polymer having at least 2() one active sulfone rnoiety that is selective for reaction with thiol moieties,. and at least one other moiety that is selective for react_~on with amino moieties, wherein said at least one active suT_fone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
-~b- 217620 In accordance with another aspect of the invention, a biomatc:rial comprising a surface and at least one water-soluble polymer derivative linked to said surface, said polymer derivai~ive comprising of a polymer selected from the group cons_LSting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) and having at least one active sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from <~ molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the invention, a method for synthesizing a hydrolytically stable water soluble activ<~ted polymer having an active sulfone moiety, the method comprising the step of attaching a linking moiety containing an active sulfone moiety and a different active mo_Lety to a polymer derivative selected from the group cons_Lsting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) having a functional group other than a sulfone moiety and wherein the functional group is selective for other active moiety on said linker moiety.
In accordance with an aspect of the invention, a method for preparing a conjugate of a substance and a water soluble activated polymer selected from the group consisting of poly(alkylene ox~_des), poly(oxyethylated polyols), and poly(olefinic alcohols) having at least one sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or i:~ derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage, said method comprising the steps 217b203 -7c-of reacting the substance with the activated polymer having a active sulfone moiety arid forming a linkage between the substance and the polymer derivative.
In accordance with another aspect of the invention, a method for preparing a conjugate of a bioljogically active molecule and an active derivative of polyi(ethylene glycol), said method comprising the steps of reaching a biologically active molecule having a reactive thio~. moiety with a polyethylene glycol) derivative having an active sulfone moiety and forming a linkage between the thio~. moiety and the active sulfone moiety, wherein said at lea s one active sulfone moiety is an active ethyl sulfone, or i derived from a molecule having a vinyl sulfone group and non-vinyl active group linked to the vinyl sulfone grow for reaction with said polymer to form an ester or amide linkage.
In accordance with another aspect of the inveltion, a h drol ticall stable biolo is Y Y Y a g ally active conjugate that is the reaction product of 1) at least one biolo ically active molecule having the structure W-SH, where'n W- is a biologically active moiety and -SH is a react've thiol moiet y, and 2) a polyethylene glycol) deriv tive activated with one or mare sulfone moieties and havin the structure:
R-CHy-CH2 (OCHzCH2) n-Y
where'In n equals 5 to 3,000 Y is -S _ 02-CH=CHa, and R i s X
CH2-CH -S02-, wherein X is halogen, and wherein said reactive thiol moiety is linked to said at least one active sulfone moietv~.
In accordance with an aspect of the invention, a method for preparing a biologically active conjugate of at least ne biologically active molecule having the structure -~d' W-SH, wherein W- is. a biologically active moiety and -SH is an active thiol moiety, and an activated polyethylene glycol) derivative having at least one active sulfone moiety, the activated polyethylene glycol) derivative havijng the structure R-CH2CHz-(OCH2CH2)"-Y, wherein n equals 5 t ' 3, 000, Y is -SOz-CFi=CH2, and R is X-CHZ-CHZ-S02--, whe ein X is halogen, said method comprising the steps of reacting the biologically active molecule with the activated polyethylene glycol) derivative and forming a linkage betty en the active thiol moiety and the at least one active sulf ne moiety of the polyethylene glycol).
Tn accordance with another aspect of the inve tion, a method of preparing a biologically active conj gate having the structure;
prot in-S-CHz-CHZ-SOZ-CH2-CHz- (OCHZCH2) n-SOz-CHZ-CHZ-S-protein, wher in n equals 5 to 3,000, the method comprising the steps of 1) reactivating at least one protein having an active thio moiety with a sulfone activated polyethylene glycol) deri ative having the structure R-CHZCHZ-(OCH2CH2)n-SOz-CH=CH , wherein R is X-CH2-CHz-SOz, and wherein X is halogen, and 2) forming a linkage between the active thiol moiety of the p otein and the active sulfone moieties of the activated polym, r.
In accordance with another aspect of the inven ion, a method for preparing a biologically active conju ate having the structure H3C0-CHz-CH2- ( OCHzCH2) "-SOZ-CH2-CHZ-S-protein where n n equals 5 to 3,000, the method comprising the steps of 1} reacting a protein having an active Lhidl moiety with an activated poly(et:hylene glycol) derivative having the struct re H3C0-CH2-CHZ- ( OCHZCHZ ) "-SOz-CH=CHZ, wherein the vinyl ulfone moiety is derived from an active ethyl sulfone group, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moiety of the act vated polymer.
In accordance with another aspect of the inn ntion, a pharmaceutical composition comprising a hyd olytically stable, biologically active conjugate, said conjugate comprising of:
a biologically active molecule having a reactive 20 thio moiety or amino moiety; and a water-;soluble polymer derivative having an acti a sulfone moiety forming a covalent linkage with said thio moiety or amino moiety.
Tn accordance with another aspect of the rove tion, a water soluble hydrolytically stable activated poly er comprising at least one active sulfone moiety cova ently linked t:o a polymer selected from the group cons sting of poly;alkylene oxidesy, poly(oxyethylated poly 1s), and poly(;olefinic alcohols), wherein said at least one active sulfone moiety is a vinyl sulfone derived from an actin ethyl sulfon,e group linked to said polymer.
Specific sulfone moieties for the activated polym rs of the invention are those having at least two carbo atoms joined to the sulfone group -SOa- with a react ve site for thiol specific coupling reactions on the secon carbon from the sulfone group.
More specifically, the active sulfone moieties compr'se vinyl sulfone, the active ethyl sulfones, including the h loethyl sulfones, and the thiol-specific active derivatives of these sulfones. The vinyl sulfone moiety can be rep esented stru<aurally as -SOz-CH=CH2; the active ethyl sulfon moiety can be represented structurally as -SOZ-CHZ-CHZ--Z, where Z can be halogen or some other leaving group J
21762p3 -? f-capable of substitution by thiol to form the sulfone and'. thiol linkage ~-SO=-CHI-CHx-s-W, where W represents a bio ogically active molecule, a surface, or some other sub tance. The derivatives of the vinyl and ethyl sul ones can include other substituents~ so long as the wat r solubility and the thiol-specific reactivity of the reactive site on the second carbon are maintained.
The invention includes hydrolytically stable con ugates of substances having thiol moieties with pol er derivative;s having active sulfone moieties.
For example, a wat~~_r soluble sulfone-activated PEG
pol er can be coupled to a biologically active mole ule at a xeac'tive thiol site. The linkage by whic the PEG and the biologically active molecule are 15. coup ed includes a sulfone moiety coupled to a thiol moie y and has the s~xucture PEG-S0,-CH,-CH~-S-W, where W re resents the b.i,ologically active molecule, whether tha ulfone moiety prior to coupling of the PEG was viny sulfonn or an active ethyl sulfone. _' The invention also includes biomaterials comprising a surface having one or more reactive thiol site'~~, and oae or more of the water soluble sulfone-WO 95/13312 PCT/US94l13013 _g_ activated polymers of the invention coupled to the surface by a sulfone and thiol linkage. Biomaterials and other substances can also be coupled to the sulfone activated polymer derivatives through a linkage other than the sulfo:ne and thiol linkage, such as a conventional amino linkage, to leave a more hydrolytically stable activating group, the sulfone moiety, available for subsequent reactions.
The invention includes a method of synthesizing the activated polymers of the invention.
A sulfur containing moiety is bonded directly to a carbon atom of the polymer and then converted to the active sulfone moiety. Alternatively, the sulfone moiety can be prepared by attaching a linking agent that has the sulfone moiety at one terminus to a conventional activated polymer so that the resulting polymer has the sulfone moiety at its terminus.
More specifically, a water soluble polymer having at least one active hydroxyl moiety undergoes a reaction to produce a substituted polymer having a more reactive moiety thereon. The resulting substituted polymer undergoes a reaction to substitute for the more reactive moiety a sulfur-containing moiety having at least two carbon atoms where the sulfur in the sulfur-containing moiety is bonded directly to a carbon atom of the polymer. The sulfur-containing moiety then undergoes reactions to oxidize sulfur, -S-, to sulfone, -SOz-, and to provide a sufficiently reactive site on the second carbon atom of the sulfone containing moiety for formation of linkages with thiol containing moieties.
Still more specifically, the method of synthesizing the activated polymers of the invention comprises reacting polyethylene glycol) with a hydroxyl activating compound to form an ester or with a halogen containing derivative to form a.halogen substituted PE;G. The resulting activated PEG is then.
reacted with mercaptoethanol to substitute the mercaptoethanol radical for the ester moiety or the halide. The sulfur in the mercaptoethanol moiety is oxidized to su=Lfone. The ethanol sulfone is activated by either activating the hydroxyl moiety or substituting t)Ze hydroxyl moiety with a more active moiety such as halogen. The active ethyl sulfone of PEG can then be converted to vinyl sulfone, if desired, by cleaving thc~ activated hydroxyl or other active moiety and introducing the carbon-carbon double bond adj acent the sulfone group -SOZ- .
The :invention also includes a method for preparing a conjugate of a substance with a polymer derivative thaw' has an active sulfone moiety. The method includes the step of forming a linkage between the polymer derivative and the substance, which linkage can be between the sulfone moiety and a thiol moiety.
Thus the invention provides activated polymers that are specific in reactivity, stable in water, stable .in reducing environments, and that form more stable linkages with surfaces and molecules, including biologically active molecules, than previously has been achieved. The activated polymer can be used to modify the characteristics of surfaces and molecules where biocompatibility is of importance.
Because the activated polymer is stable under aqueous conditions and forms stable linkages with thiol moieties, the 'most favorable reaction conditions can be selected for preserving activity of biologically active substances and for optimizing the rate of reaction for polymer coupling.
Detailed DescriQ,tion of the invention The synthetic route used to prepare active sulfones of polyethylene glycol) and related polymers comprises at least four steps in which sulfur is bound to a polymer molecule and then converted through a series of reactions to an active sulfone functional WO 95!13312 217 6 2 0 3 pCTlUS94/13013 group. The starting PEG polymer molecule has at least one hydroxyl moiety, -OH, that is available to participate in chemical reactions and is considered to be an "active" hydroxyl moiety. The PEG molecule can have multiple active hydroxyl moieties available for chemical reaction, as is explained below. These active hydroxyl moieties are in fact relatively nonreactive, and the first step in the synthesis is to prepare a PEG
having a more reactive moiety.
A more reactive moiety typically will be created by one of two routes, hydroxyl activation or substitution. Other methods are available as should be apparent to the skilled artisan, but hydroxyl activation and substitution are the two most often used. In hydroxyl activation, the hydrogen atom -H on the hydroxyl moiety -OH is replaced with a more active group. Typically, an acid or an acid derivative such as an acid halide is reacted with the PEG to form a reactive ester in which the PEG and the acid moiety are linked through the ester linkage. The acid moiety generally is more reactive than the hydroxyl moiety.
Typical esters are the sulfonate, carboxylate, and phosphate esters.
Sulfonyl acid halides that are suitable for use in practicing the invention include methanesulfonyl chloride and p-toluenesulfonyl chloride. Methanesulfonyl chloride is represented structurally as CH3SOZC1 and is also known as mesyl chloride. Methanesulfonyl esters are sometimes referred to as mesylates. Para-toluenesulfonyl chloride is represented structurally as H3CC6H4SOZC1 and is also known as tosyl chloride. Toluenesulfonyl esters are sometimes referred to as tosylates.
In a substitution reaction, the entire -OH
group on the PEG is substituted by a more reactive moiety, typically a halide. For example, thionyl chloride, represented structurally as SOC12, can be 211b203 xea~ted with PEG to form a more reactive chlorine substituted PEG. Substitution of the hydroxyl moiety by another moiety is siometimee referred to in the art as hydroxyl activatior.~. The term "hydroxyl activation" should be interpreted herein to mean substitution as well as estejrification and other methods of hydroxyl activation.
The terms "group," "functional group," "moiety,"
"actjive moiety," "reactive site," and "radical" are somewhat.
eyno ymous in the chemical arts and are used in the art and here'n to refer to distinct, definable portions or unite of a molecule and to unite that perform some function or acts ity and are reactive with other molecules or portions of m lecules. Tn this sense a protein or a protein residue can a considered a molecule or as a functional ,group or mole y when coupled to a polymer.
The term '''PEGS' is used in the art and herein to desc ibe any of several condensation polymers of ethylene glyco having the general formula represented by the strut ure H(OCH,CHs) nOH, which can also be represented as HO-CH CH,- (OCHaCHa) r~-OH. PEG is also known as polyo yethylene, polyethylene oxide, polyglycol, and polye her glycol. PEG can be prepared as copolymers o.f ethyl ne oxide and many other monomers.
Polyethylene glycol) is used in biological applications because it has properties that are highly desire 1e and is generally approved for biological or biotec nical applicat:ione. PEG typically is clear, -11a-colorless, odorles:~; soluble in water, stable to heat, inert to many chemical agents, does not hydrolyze or deteriorate, and ie nontoxic. F~oly(ethylene glycol) is considered to be biocompatible., which is to say that PEG ie capable of coe~ietence with living tissues or organisms without causing harm. More specifically, PEG is nat immunogenic, which is to s;ay that PEG dose not tend to produce an immune response in t~e body. When attached to a moiety having some degi~able function in WO 95/13312 ~ 217 6 2 0 3 p~/US94/13013 the body, the PEG tends to mask the moiety and can reduce or eliminate any immune response so that an organism can tolerate the presence of the moiety.
Accordingly, the sulfone-activated PEGs of the invention should be substantially non-toxic and should not tend substantially to produce an immune response or cause clotting or other undesirable effects.
The second step in the synthesis is to link sulfur directly to a carbon atom in the polymer and in a form that can be converted to an ethyl sulfone or ethyl sulfone derivative having similar reactive properties. "Ethyl" refers to a moiety having an identifiable group of two carbon atoms joined together.
The active sulfone PEG derivative requires that the second carbon atom in the chain away from the sulfone group provide a reactive site far linkages of thiol moieties with t:he sulfone. This result can be achieved by reacting the active moiety produced in the first step mentioned .above, which typically will be the ester or halide substituted PEG, in a substitution reaction with an alcohol that also contains a reactive thiol moiety attached to an ethyl group, a thioethanol moiety. The thiol moiety is oxidized to sulfone and the second carbon away from the sulfone on the ethyl group is converted to a reactive site. , Compownds containing thiol moieties, -SH, are organic compounds that resemble alcohols, which contain the hydroxyl moiety -OH, except that in thiols, the oxygen of at least one hydroxyl moiety is replaced by sulfur. The activating moiety on the PEG derivative from the first :reaction, which typically is either halide or the acid moiety of an ester, is cleaved from the polymer and is replaced by the alcohol radical of the thioethanol compound. The sulfur in the thiol moiety of the alcohol is linked directly to a carbon on the polymer.
WO 95/13312 217 6 2 0 3 1'CTIUS94/13013 The alcohol should be one that provides a thioethanol moiety for attachment directly to the carbon of the polymer chain, or that can easily be converted to a thioethanol moiety or substituted moiety of similar reactive properties. An example of such an alcohol is mercaptoethanol, which is represented structurally as HSCHZCHZOH and is sometimes also called thioethanol.
In the third step of the synthesis, an oxidizing agent is used to convert the sulfur that is attached to the carbon to the sulfone group, -SO2.
There are many such oxidizing agents, including hydrogen peroxide and sodium perborate. A catalyst, such as tungst:ic acid, can be useful. However, the sulfone that i;~ formed is not in a form active for thiol-selective reactions and it is necessary to remove the relatively unreactive hydroxyl moiety of the alcohol that was added in the substitution reaction of the second step.
In tine fourth step, the hydroxyl moiety of the alcohol that was added in the second step is converted to a more reactive form, either through activation of 'the hydroxyl group or through substitution of the hydroxyl group with a more reactive group, similar to the first step in the reaction sequence. Substitution typically is with halide to form a haloethyl sulfone or a derivative thereof having a reactive site on the second carbon removed from the sulfone moiety. Typically, the second carbon on the ethyl group will be activated by a chloride or bromide halogen. Hydroxyl activation should provide a site of similar reactivity, such as the sulfonate ester.
Suitable reactants are the acids, acid halides, and others previously mentioned in connection with the first step in the reaction, especially thionyl chloride for substitution of the hydroxyl group with the chlorine atom.
WO 95/13312 2 ~ ~ 6 2 ~ PCTIUS94/13013 The resulting polymeric activated ethyl sulfone is stable, isolatable, and suitable for thiol-selective coupling reactions. As shown in the examples, PEG chloroethyl sulfone is stable in water at a pH of about 7 or less, but nevertheless can be used to advantage for thiol-selective coupling reactions at conditions of basic pH up to at least about pH 9.
In the thiol coupling reaction, it is possible that the thiol moiety displaces chloride, as in the following reaction:
PEG-SOz-CHZ-CHZ-C1 + W-S-H -j PEG-S02-CHz-CHZ-S-W, where W represents the moiety to which the thiol moiety SH is linked and can be a biologically active molecule, a surface, or some other substance. However, and while not wishing to be bound by theory, it is believed, based on the observable reaction kinetics as shown in Example 3, that the chloroethyl and other activated ethyl sulfones and reactive derivatives are converted to PEG vinyl sulfone, and that it is the PEG vinyl sulfone or derivative thereof that is actually linked to the thiol moiety. Nevertheless, the resulting sulfone and thiol linkage is not distinguishable, whether from active PEG ethyl sulfone or from PEG vinyl sulfone, and so the active ethyl sulfone can be used at pHs above 7 for linking to thiol groups.
PEG vinyl sulfone is also stable and isolatable and can form thiol-selective, hydrolytically stable linkages, typically in much less time than the haloethyl sulfone or other activated ethyl sulfone, as explained further below.
In a fifth step that can be added to the synthesis, the activated ethyl sulfone is reacted with any of a variety of bases, such as sodium hydroxide or triethylamine, to form PEG vinyl sulfone or one of its active derivatives for use in thiol-selective coupling reactions.
WO 95!13312 21 ~ 6 2 0 3 PCT/I1S94/13013 As shown in the examples below, especially Example 3, PEG vinyl sulfone reacts quickly with thiol moieties and is stable against hydrolysis in water of pH less than about 11 for at least several days. The reaction can be. represented as follows:
PEG-S02-CH=CH2 + W-S-H --~ PEG-S02-CHz-CHZ-S-W.
The thiol moiety is said to add "across the double bond." The W-S moiety adds to the terminal CHz of the double bond, which is the second carbon from the sulfone group 502. The hydrogen H adds to the CH of the double bond. However, at a pH of above about 9, selectivity of the sulfone moiety for thiol is diminished and the sulfone moiety becomes somewhat more reactive with amino groups.
Alternatively to the above synthesis, the sulfone-activated PEG derivatives can be prepared by attaching a linking agent having a sulfone moiety to a PEG activated with a different functional group. For example, an amino activated PEG, PEG-NH2, is reacted under favorable' conditions o:E pH of about 9 or less with a small molecule that has a succinimidyl active ester moiety NF~S-02C- at one terminus and a sulfone moiety, vinyl :~ulfone -SOZ-CH=CH2, at the other terminus. The amino activated PEG forms a stable linkage with the succinimidyl ester. The resulting PEG
is activated with the vinyl sulfone moiety at the terminus and i:~ hydrolytically stable. The reaction and the resulting vinyl sulfone activated PEG are represented stx-ucturally as follows:
PEG-NHz + NHS-OzC-CH2-C:Eiz-S02-CH=CHZ
PEG-NH-OC-CH2-CHz-SOz-CH=CH2.
A similar activated PEG could be achieved by reacting an amine-activated PEG such as succinimidyl active ester PE:G, PEG-COZ-NHS, with a small molecule that has an amine moiety at one terminus and a vinyl sulfone moiety at the other terminus. The succinimidyl WO 95/13312 21 l 6 2 ~ 3 PCTIUS94113013 ester forms a stable linkage with the amine moiety as follows : PEG-CO2-NHS + NHZ-CHZ-CH2-S02-CH=CHZ -~
PEG- CO-NH- CH2-CHZ-SOZ- CH=CHZ .
The active PEG sulfones of the invention can be of any molecular weight and can be linear or branched with hundreds of arms. The PEG can be substituted or unsubstituted so long as at least one reactive site is available for substitution with the sulfone moieties. PEG typically has average molecular weights of from 200 to 100,000 and its biological properties can vary with molecular weight and depending on the degree of branching and substitution, so not all of these derivatives may be useful for biological or biotechnical applications. For most biological and biotechnical applications, substantially linear, straight-chain PEG vinyl sulfone or bis vinyl sulfone or activated ethyl sulfone will be used, substantially unsubstituted except for the vinyl sulfone or ethyl sulfone moieties and, where desired, other additional functional groups. For many biological and biotechnical applications, the substituents would typically be unreactive groups such as hydrogen H- and methyl CH3- ( "m-PEG" ) .
The PEG can have more than one vinyl sulfone or precursor moiety attached or the PEG can be capped on one end with a relatively nonreactive moiety such as the methyl radical, -CH3. The capped form can be useful, for example, if it is desirable simply to attach the polymer chains at various thiol sites along a protein chain. Attachment of PEG molecules to a biologically active molecule such as a protein or other pharmaceutical or to a surface is sometimes referred to as "PEGylation."
A linear PEG with active hydroxyls at each end can be activated at each end with vinyl sulfone or its precursor or derivatives of similar reactivity to become bifunctional. The bifunctional structure, PEG
2~ ~6~03 bis vinyl sulfonE~, for example, is sometimes referred to as a dumbbell structure and can be used, for example, as a linker or spacer to attach a biologically active molecule t:o a suxface or to attach more than one such biologically active molecule to the PEG molecule.
The stability of the sulfone moiety against hydrolysis ma es it particu:lariy useful fox bi-functional or he exobifunc~ion~~l applications.
Another application for PEG vinyl sulfone and it precursor is dendritic activated PEG in which mu tiple arms of PEG are attached to a central core st ucture. l7end:ritic PEG structures can be highly br nched and are commonly known as ~~star~~ molecules.
Star molecules era generally described in Merrill U.S.
Patient No. 5,171,264. The sulfone moieties can be used to pro~ride an active, functional group on the end of the PEG
chain extending from the core and as a linker for joining a functional group to the star molecule arms.
PEG vinyl sulfone and its precursors and der natives can ;be used for attachment directly to sur aces and mohecules having a thiol moiety. However, mor typically a heterobifunctional PEG derivative hav'ng a eulfone moiety on one terminus and a different fun tional moiety on the opposite terminus group will be attached by t:he different moiety to a surface or mole ule. When substituted with one of the other acts a moieties, the heterobifunctional PEG dumbbell stru ture.can be used, fox example, to carry a protein or o her biologically active molecule by sulfone link ges on one ,and and by another linkage on the other end, such as an .amine linkage,~to produce a molecule havi g two different activities. A heterobifunctivnal PEG awing a sul:fone moiety on one end and an amine spec fic moiety on the other end could be attached to both cysteine and lysine fractions of proteins. A
stable amine linkage can be achieved and then the hydrolytically stable unreacted sulfone moiety is available for subsequent thiol-specific reactions as desired.
Other aci~ive groups for heterobifunctional sulfone-activated PEGS can be selected from among a wide variety of compounds. For biological and biotechnical applications, the substituents would typically be selected from reactive moieties typically used in PEG chemistry to activate PEG such as the aldehydes, l~rifluoroethylsulfonate, which is also sometimes called tresylate, n-hydroxylsuccinimide ester, cyanuric chloride, cyanuric fluoride, aryl azide, succinate, the p-diazo benzyl group, the 3-(p-diazophenyloxy)-2-hydroxy propyloxy group, and others.
Examples of active moieties other than sulfone are shown .in Davis et al. U.S. Patent No.
4,179,337; Lee et <~l. U.S. Patent Nos. 4,296,097 and 4,430,260; Iwasaki at al. 4,670,417; Katre et al. U.S.
Patent Nos. 4,766,:106; 4,917,888; and 4,931,544;
Nakagawa et al. U.S. Patent No. 4,791,192; Nitecki et al. U.S. Patent No. 4,902,502 and 5,089,261; Saifer U.S. Patent No. 5,080,891; 2alipsky U.S. Patent No.
5,122,614; Shadle et al. U.S. Patent No. 5,153,265;
Rhee et al. U.S. Patent No. 5,162,430; published European Patent Application Publication No. 0 247 860; and published WO 8700056, WO 9004606, WO 9004384, WO 9107190, WO 9204384, WO 9213095 and WO 9216555.
It should be apparent to the skilled artisan that the dumbbell strucl~ures discussed above could be used to carry a wide variet=y of substituents and combinations of substituents. Pharmaceuticals such as aspirin, vitamins, penicillin, and others too numerous to mention; polypeptides or proteins and protein fragments of various functionalities and molecular v weights; cells of various types; surfaces for biomaterials, almøst any eubstanc~e could be modified. As used herein, the term "protein" sho~;~,ld be understood to include peptides and pol~peptides, which are polymers of amino acids. The term "bi material" mean's a material, typically synthetic and som times made of plastic, that is suitable for implanting in living body to repair damaged or diseased parts. An exa 1e of a biomat.erial is artificial blood vessels.
One straight chain PEG derivative of the invention for iological and biotechnical applications has the basic stru tune R-CHaCH'- ~;OCHaCHs) "-Y. The PEG monomer OCHzCH~
pref rably is substantially unsubstituted and unbranched alon the polymer backbone. The subscript "n" can equal from about 5 to 3,000. A more typical range is from about 5 to 2,200, which corresponds to a molecular weight of from abou 220 to 100,000. Still more typical is a range of from about 34 to 1,100, which corresponds to a molecular weight range of from about 1,500 to 50,000. Most applications will be ac omplished with molecular weights in the neighborhood of 2, 00 to 5;000, which corresponds to a value of n of from about 45 to 110.
In the above structure, Y represents -SOa- CH=CHI
or -S a-CHa-CHz-X where X is a halogen. R repregenta a group that ay be the same or different from Y. R can be HO-, H3 C0-, CHz=CH-SO,-, C1-CHa-CHa-SOz-, or a polymer activating _. ._ . ,~
-__ _ ..~~ . : ~ .
-19a-group other than C;Ha=CH-Saa-,C1-CHs-CHI-SOz-, such as is referred to with respect to the above patents and published patent applications.
The act:_ve polymer derivatives are water soluble and.hydrolyticall;r stable and produce water soluble and hydxolytically stable linkages with thiol groups. The derivatives are considered infinitely soluble in water or as approaching infinite solubility and can enable atherwiee insoluable molecules to page into solution when conjugated with. the derivative.
r _:.,., . . w 217 b203 WO 95113312 PCTlUS94113013 Hydrc>lytic stability of the derivatives means that the linkage between the polymer and the sulfone moiety is stable in water and that the vinyl sulfone moiety does not: react with water at a pH of less than about 11 for arL extended period of time of at least several days, and potentially indefinitely, as shown in Example 3 below. The activated ethyl sulfone can be converted to the vinyl sulfone at conditions of basic pH, with the same resulting stability. Hydrolytic stability of the thiol linkage means that conjugates of the activated polymer and a substance having a thiol moiety are stable at the sulfone-thiol linkage for an extended period of time in aqueous environments at a pH
of below about 11. Most proteins could be expected to lose their activity at a caustic pH of 11 or higher, so it should be apparent to the skilled artisan that many applications for the active sulfone PEG derivatives will be at pHs of less than 11, regardless of the stability of the sulfone moiety at higher pH.
To be useful for modification of proteins and other substance=s, it is only necessary that the sulfone be stable for a period of time sufficient to permit the sulfone to react with a reactive thiol moiety on the protein or other substance. The rate of reaction of the sulfone moiety with thiol can vary with pH, as shown in Examp:Le 2 below, from about 2 minutes to 30 minutes, which is much faster than the rate of hydrolysis, if any. Vinyl sulfone could be expected to react with thiol over a much broader range of reaction times since it is stable for long periods of time.
Also, as shown in Example 3 below, at conditions of basic pH chloroethyl sulfone is not hydrolyzed, but is converted to vinyl sulfone, which remains stable for several days a:nd is even more reactive toward thiol groups. Accordingly, for the purpose of modifying the characteristics of substances, the active ethyl sulfones can also be considered to be hydrolytically stable for an extended period of time over a broad pH
range.
Other water soluble polymers than PEG are believed to be suitable for similar modification and activation with an active sulfone moiety. These other polymers include polyvinyl alcohol) ("PVA"); other poly(alkylene oxides) such as polypropylene glycol) ("PPG") and the: like; and poly(oxyethylated polyols) such as poly(o~:yethylated glycerol), poly(oxyethylated sorbitol), and poly(oxyethylated glucose), and the like. The polymers can be homopolymers or random or block copolymers and terpolymers based on the monomers of the above polymers, straight chain or branched, or substituted or unsubstituted similar to PEG, but having at least one a<aive site available for reaction to form the sulfone mo~~ety.
The i:ollowin.g Example 1 shows the synthesis, isolation, and characterization of polyethylene glycol) chloroethyl sulfone followed by the preparation of polyethylene glycol) vinyl sulfone from the chloroethyl sulfone. Preparation of other polymeric sulfones having a reactive site on the second carbon from the sulfone group is similar and the steps for doing so should be apparent to the skilled artisan based on Examp:Le 1 below and the polymers listed above.
Example 1: Synthesis The .reaction steps can be illustrated structurally as follows:
( 1 ) PEG-OH + CH3SOZC1 ~ PEG-OSOzCH3 (2) PEG-OSO.,CH3 + HSCHZCH20H ~ PEG-SCHZCHZOH
(3) PEG-SCH.;CHzOH + H202 ~ PEG-SOZCHZCH20H
(4) PEG-SOZC:HzCH20H + SOC12 ~ PEG-SOZCHzCH2C1 ( 5 ) PEG-SOz- CHZCHzCl + NaOH ~ PEG-SOz-CH=CHz + HC1 Each of the above reactions is described in detail below:
Reaction 1. Reaction 1 represents the preparation of the methane sulfonyl ester of polyethylene glycol), which can also be referred to as the methanesulfonate or mesylate of polyethylene glycol). The tosylate and the halides can be prepared by similar procedures, which are believed to be apparent to the skilled artisan.
To prepare the mesylate, twenty-five grams of PEG of molecular weight 3400 was dried by azeotropic distillation in 150 ml of toluene. Approximately half of the toluene was distilled off in drying the PEG.
Forty ml of dry dichloromethane was added to the toluene and PEG solution, followed by cooling in an ice bath. To the cooled solution was added 1.230 ml of distilled methanesulfonyl chloride, which is an equivalent weight of 1.06 with respect to PEG hydroxyl groups, and 2.664 ml of dry triethylamine, which is an equivalent weight of 1.3 with respect to PEG hydroxyl groups. "Equivalent weight" as used above can be thought of as "combining weight" and refers to the weight of a compound that will react with an equivalent weight of PEG hydroxyl groups.
The reaction was permitted to sit overnight during which time it warmed to room temperature.
Triethylammonium hydrochloride precipitated and the precipitate was removed by filtration. Thereafter, the volume was reduced by rotary evaporation to 20 ml. The mesylate was precipitated by addition to 100 ml of cold dry ethyl ether. Nuclear magnetic resonance (NMR) analysis showed 1000 conversion of hydroxyl groups to mesylate groups.
Reaction 2. Reaction 2 represents the formation of polyethylene glycol) mercaptoethanol by reaction of the mesylate with mercaptoethanol. The reaction causes the methanesulfonate radical to be displaced from the PEG. The sulfur in the mercaptoethanol radical is attached directly to the carbon in the carbon-carbon backbone of the PEG.
WO 95113312 ~ 17 6 2 0 3 PCT/US94/13013 Twenty grams of the mesylate from reaction 1 was dissolved un 150 ml of distilled water. The solution of me;~ylate a.nd water was cooled by immersion in an ice bath., To the cooled solution was added 2.366 ml of mercaptoethanol, which is 3 equivalent weights with respect to PEG :hydroxyl groups. Also added was 16.86 ml of 2N NaOH base. The reaction was refluxed for 3 hours, which means that the vapors rising from the reaction were continuously condensed and allowed to flow back into the reaction.
The polyethylene glycol) mercaptoethanol product was ext:racted three times with dichloromethane using approximately 25 ml of dichloromethane each time.
The organic fractions were collected and dried over anhydrous magnesium sulfate. The volume was reduced to ml and the product was precipitated by addition to 150 ml of cold dry ether.
NMR analysis in d6-DMSO dimethyl sulfoxide gave the following peaks for PEG-SCH2CH20H: 2.57 ppm, 20 triplet, -CH2-~~-; 2.65 ppm, triplet, -S-CH2-; 3.5 ppm, backbone singlc~t; and 4.76 ppm, triplet, -OH. The hydroxyl peak at 4.76 ppm indicated 81% substitution.
However, the 2.65 ppm peak for -S-CH2- indicated 100%
substitution. It has been observed that hydroxyl peaks frequently give low figures on percent substitution, and so the 2.65 ppm peak for -S-CH2- is considered to be more reliable .and to confirm 100% substitution.
Reaction 3. Reaction 3 represents peroxide oxidation of t:he polyethylene glycol) mercaptoethanol product to convert the sulfur, S, to sulfone, 502. PEG
ethanol sulfone is produced.
Twenty grams of PEG-SCH2CH20H was dissolved in 30 ml of 0.123.M tungstic acid solution and cooled in an ice bath. The tungstic acid. solution was prepared by dissolving the acid in sodium hydroxide solution of pH
11.5 and then adjusting the pH to 5.6 with glacial acetic acid. Twenty ml of distilled water and 2.876 ml of 30% hydrogen. peroxide, which has an equivalent weight of 2.5 with respect to hydroxyl groups, was added to the solution of tungstic acid and polyethylene glycol) mercaptoethanol and the.reaction was permitted to warm overnight to room temperature.
The oxidized product was extracted three times with dichloromethane using 25 ml of dichloromethane each time. The collected organic fractions were washed with dilute aqueous sodium bicarbonate and dried with anhydrous magnesium sulfate.
The volume was reduced to 20 ml. The PEG ethanol sulfone product was precipitated by addition to cold dry ethyl ether.
NMR analysis in d6-DMSO dimethyl sulfoxide gave the following peaks for PEG-S02CHZCHzOH: 3.25 ppm, triplet, -CH2-SOZ-; 3.37 ppm, triplet, -SOZ-CHZ-; 3.50 ppm, backbone; 3.77 ppm, triplet, -CHzOH; 5.04 ppm, triplet, -OH. The hydroxyl peak at 5.04 ppm indicated 85a substitution. However, the peak at 3.37 ppm for -SOZ-CHz- indicated 1000 substitution and is considered to be more reliable.
Reaction 4. Reaction 4 represents the final step in synthesis, isolation, and characterization of polyethylene glycol) chloroethyl sulfone.
To synthesize the product, twenty grams of PEG-S02CHZCHZOH poly (ethylene glycol) ethanol sulfone was dissolved in 100 ml of freshly distilled thionyl chloride and the solution was refluxed overnight. The thionyl chloride had been distilled over quinoline.
Excess thionyl chloride was removed by distillation.
Fifty milliliters of toluene and 50 ml of dichloromethane were added and removed by distillation.
To isolate the product, the PEG chloroethyl sulfone was dissolved in 20 ml of dichloromethane and precipitated by addition to 100 ml of cold dry ethyl ether. The precipitate was recrystallized from 50 ml of ethyl acetate to isolate the product.
WO 95!13312 PCT/US94113013 Nucle:ar magnetic resonance was used to characterize the product. NMR analysis of PEG-SOZCHZCHzCl in d6-DMSO dimethyl sulfoxide gave the following peaky>: 3.50 ppm, backbone; 3.64 ppm, triplet, -CHZSOz-; 3.80 ppm, 'triplet, -SOz-CH2-. A small hydroxyl impurity triplet appeared at 3.94 ppm.
Calculation of the percentage substitution was difficult for t=his spectrum because of the proximity of the important peaks to the very large backbone peak.
React:ioa 5. Reaction 5 represents conversion of polyethylene glycol) chloroethyl sulfone from reaction step ~: to polyethylene glycol) vinyl sulfone and isolation and characterization of the vinyl sulfone product.
The PEG vinyl sulfone was readily prepared by dissolving solid PEG chloroethyl sulfone in dichloromethane solvent followed by addition of two equivalents of NaOH base. The solution was filtered to remove the base and the solvent was evaporated to isolate the final product PEG-SOZ-CH=CH2 PEG vinyl sul f one .
The T?EG vinyl sulfone was characterized by NMR analysis in d6-DMSO dimethyl sulfoxide. NMR
analysis showed the following peaks: 3.50 ppm, backbone; 3.73 ppm, triplet, -CH2-SOZ-; 6.21 ppm, triplet, =CH2; 6.97 ppm, doublet of doublets, -S02-CH-.
The 6.97 ppm pe=ak for -SOZ-CH- indicated 84%
substitution. The 6.21 ppm peak for =CH2 indicated 940 substitution. Titration with mercaptoethanol and 2,2'-dithiodip;rridine indicated 95o substitution.
Example 2: Thiol-selective Reactivity Example 2 shows that PEG vinyl sulfone and its precursor l?EG chloroethyl sulfone are significantly more reactive with thial groups (-SH) than with amino groups (-NHZ) or imino groups (-NH-). Compounds containing thiol groups are organic compounds that resemble alcohols, which contain the hydroxyl group WO 95!13312 217 6 2 0 3 pCT/US94/13013 -OH, except that in thiols, the oxygen of the hydroxyl group is replaced by sulfur. Thiols sometimes are also called sulfhydryls or mercaptans. PEG vinyl sulfone contains the vinyl sulfone group -S02-CH=CHz. PEG
chloroethyl sulfone contains the chloroethyl sulfone group -SOZCHZCH2C1.
Selectivity for thiols is important in protein modification because it means that cysteine units (containing -SH) will be modified in preference to lysine units (containing -NHZ) and histidine units (containing -NH-). The selectivity of PEG vinyl sulfone for thiols means that PEG can be selectively attached to cysteine units, thus preserving protein activity for specific proteins and controlling the number of PEG molecules attached to the protein.
The relative reactivity of PEG vinyl sulfone with thiol and amino groups was determined by measuring the rates of reaction of PEG vinyl sulfone with N-a-acetyl lysine methyl ester and with mercaptoethanol. N-a-acetyl lysine methyl ester is a lysine model containing an amino group and is abbreviated Lys-NH2. Mercaptoethanol serves as a cysteine model containing a thiol group and is abbreviated Cys-SH. Relative reactivity of PEG
chloroethyl sulfone was similarly determined. This molecule may serve as a "protected" form of the vinyl sulfone since it is stable in acid but converts to PEG
vinyl sulfone upon addition of base.
Reactivity for PEG vinyl sulfone and for the PEG chloroethyl sulfone precursor was investigated at pH 8.0, pH 9.0, and at pH 9.5. Buffers for controlling the pH were 0.1 M phosphate at pH 8.0 and 0.1 M borate at pH 9.0 and at pH 9.5. For measurement of mercaptoethanol reactivity, 5 mM ethylenediamine tetraacetic acid (EDTA) was added to both buffers to retard conversion of thiol to disulfide.
aW0 95113312 217 6 2 0 3 F'CTIUS94113013 For reaction of the PEG derivatives of the invention with Lys-NH2, a 3 mM solution of the PEG
derivative was added under stirring to a 0.3 mM Lys-NH2 solution in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by addition of fluorescamine to the reaction solution to produce a fluorescent derivative from reaction with remaining amino groups. The monitoring step was performed by adding 50 ~L of reaction mixture to 1.950 mL of phosphate buffer of ph 8.0 followed by adding 1.0 mL of fluorescamine solution under vigorous stirring.
The fluorescamine solution was 0.3 mg fluorescamine per ml of acetone.
Fluorescence was measured 10 minutes after mixing. Excitation was shown at wavelength 390 nm.
Light emission occurred at 475 nm. No reaction was observed in 24 hours for either PEG vinyl sulfone or PEG chloroethyl sulfone at pH 8Ø At pH 9.5 the reaction was slow, but all amino groups were reacted after several days.
For reaction of the PEG vinyl sulfone and PEG
chloroethyl sulfone precursor with Cys-SH, a 2 mM
solution of the PEG derivative was added to a 0.2 mM
solution of Cys-SH in the appropriate buffer for each of the three levels of basic pH. The reaction was monitored by adding 4-dithiopyridine to the reaction solution. The 4-dithiopyridine compound reacts with Cys-SH to produce 4-th.iopyridone, which absorbs ultraviolet light.
The monitoring step was performed by adding 50~.L of reaction mixture to 0.950 mL of 0.1 M phosphate buffer at pH 8.0 and containing 5 mM EDTA, followed by adding one mL of 2 mM ~4-dithiopyridine in the same buffer.
Absorbance of 4-thiopyridone was measured at 324 nm. Both F~EG vinyl sulfone and PEG chloroethyl sulfone showed reactivity toward Cys-SH, with PEG vinyl WO 95!13312 21 l b 2 0 3 PCTIUS94I13013 -28_ sulfone showing greater reactivity. At pH 9.0 the reaction is over within two minutes using the vinyl sulfone and within 15 minutes using the chloroethyl sulfone. However, these reactions were too fast for determination of accurate rate constants. At pH 8.0 the reactions were slower, but still complete in one hour for vinyl sulfone and in three hours for the chloroethyl sulfone. The conversion of chloroethyl sulfone to vinyl sulfone is significantly slower than the reaction of vinyl sulfone with Cys-SH. Thus the rate of reaction for chloroethyl sulfone with Cys-SH
appears to be dependent on the rate of conversion of chloroethyl sulfone to vinyl sulfone. Nevertheless, these reaction rates were still much faster than for the reaction with Lys-NH2.
The above kinetic studies demonstrate the following points. PEG vinyl sulfone is much more reactive with thiol groups than with amino groups, indicating that attachment of PEG vinyl sulfone to a protein containing both cysteine and lysine groups proceeds primarily by reaction with cysteine. Since reactivity with amino groups is similar to imino groups, then reactivity of histidine subunits will also be much lower than reactivity with cysteine subunits.
Also, selectivity toward thiol groups is accentuated at lower pH values for PEG chloroethyl sulfone and PEG
vinyl sulfone, although the reactions of PEG
chloroethyl sulfone are somewhat slower.
The utility of many PEG derivatives is limited because they react rapidly with water, thus interfering with attempts to attach the derivative to molecules and surfaces under aqueous conditions. The following Example 3 shows that PEG vinyl sulfone and PEG chloroethyl sulfone are stable in water.
Example 3: Hydrolytic Stability PEG vinyl sulfone was dissolved in heavy water, D20 deuterium oxide, and monitored by NMR.
WO 95113312 217 6 2 0 3 p~'~s94113013 Reaction did not occur. A solution of PEG chloroethyl sulfone produced PEG vinyl sulfone in heavy water that was buffered with borate to pH 9Ø Monitoring with NMR showed that PEG vinyl sulfone, once produced, was stable for three days in heavy water.
PEG chloroethyl sulfone is stable in water until solution: becomes basic, at which time it is converted intc> vinyl sulfone. Conversion to vinyl sulfone has beam demonstrated by dissolving PEG
chloroethyl sulfone in water at pH 7 and in borate buffer at pH 9. The PEG derivative is extracted into methylene chloride. Removal of methylene chloride, followed by NMR analysis showed that PEG chloroethyl sulfone is stable at a neutral pH of 7.0, and reacts with base to produce PEG vinyl sulfone.
Vinyl sulfone is stable for several days in water, even at basic pH. Extensive hydrolytic stability and thiol-specific reactivity of PEG vinyl sulfone means that PEG vinyl sulfone and its precursor are useful for modification of molecules and surfaces under aqueous conditions, as shown in the following Example 4.
Example 4~ Protein Con-iuQation Protein modification was demonstrated by attachment of the PEG derivative to bovine serum albumin (BSA) by two different methods. BSA is a protein. Native unmodified BSA contains cystine groups which do not contain thiol groups. The cystine units are tied up as disulfide linkages, S-S.
In the first method, m-PEG vinyl sulfone of molecular weight 5,000 was reacted with unmodified BSA
for 24 hours in a 0.1 M borate buffer at pH 9.5 at room temperature. The solution contained 1 mg of BSA and 1 mg of m-PEG vinyl sulfone of molecular weight 5,000 per ml of solution. The results from the Example 2 model compounds had indicated that lysine subunits~ (and possibly hist~idine subunits) would be modified under WO 95/13312 21 ~ 6 2 (~ 3 these relatively basic conditions and in the absence of free thiol groups available for reaction.
Attachment to lysine subunits was demonstrated in two ways. First, size exclusion chromatography showed that the molecular weight of the protein had increased by approximately 50a, thus indicating attachment of approximately 10 PEGS to the protein. Second, fluorescamine analysis showed that the number of lysine groups in the BSA molecule had been reduced by approximately ten.
In the second method, the BSA was treated with tributylphosphine to reduce the disulfide S-S
bonds to thiol groups, -SH, which are available for reaction. The modified BSA was then treated with PEG
chloroethyl sulfone at pH 8.0 in a 0.1 M phosphate buffer at room temperature for 1 hour. The solution contained 1 mg of modified BSA and 1 mg of m-PEG
chloroethyl sulfone of molecular weight 5,000 per ml of solution. The results showed that lysine groups were unreactive under these conditions. However, thiol groups were reactive.
Attachment of the PEG to the protein was demonstrated by size exclusion chromatography, which showed an increase in the molecular weight of the protein by about 250. Fluorescamine analysis indicated no change in number of lysine subunits in the protein, thus confirming that PEG attachment did not take place on lysine subunits. Substitution on thiol groups was thereby confirmed.
The invention claimed herein has been described with respect to particular exemplified embodiments. However, the foregoing description is not intended to limit the invention to the exemplified embodiments, and the skilled artisan should recognize that variations can be made within the spirit and scope of the invention as described in the foregoing specification. On the contrary, the invention includes all alternatives, modifications, and equivalents that may be included within the true spirit and scope of the invention as defined by the appended claims.
Claims (84)
1. A water soluble hydrolytically stable activated polymer comprising at least one active sulfone moiety covalently linked to a polymer selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols), wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
2. The active polymer of claim 1 wherein said polymer is a poly(alkyleneoxide).
3. The active polymer of claim 1 where said polymer is a poly (olefinic alcohol).
4. The activated polymer of claim 3 wherein said polymer is poly(ethylene glycol) and said at least one active sulfone moiety is selected from the group consisting of vinyl sulfone and haloethyl sulfone.
5. The activated polymer of claim 1 wherein said polymer is poly(ethylene glycol) vinyl sulfone.
6. The activated polymer of claim 1 wherein said polymer is selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), poly(oxyethylated glycerol), poly(oxyethylated sorbitol), poly(oxyethylated glucose), and poly(vinyl alcohol).
7. The activated polymer of claim 1 wherein said polymer is poly(ethylene glycol).
8. The activated polymer of claim 1 wherein said polymer is a straight chain polymer.
9. The activated polymer of claim 8 wherein said straight chain polymer is linked to no other moieties than said at least one active sulfone moiety.
10. The activated polymer of claim 1 wherein the polymer is a random or block copolymer or terpolymer.
11. The activated polymer of claim 1 wherein said polymer is a dumbbell structure having said active moiety on at least one terminal end of the polymer backbone and having an active moiety that may be the same or different from said active moiety on the opposite terminal end of the polymer backbone.
12. The activated polymer of claim 11 comprising a different active moiety on the opposite terminal end of said polymer backbone that is reactive with amino moieties.
13. The activated polymer of claim 1 wherein said polymer comprises at least one arm of a branched molecular structure.
14. The activated polymer of claim 13 wherein said branched molecular structure is dendritic.
15. The activated polymer of claim 1 wherein said at least one active sulfone moiety is capable of reacting with a reactive moiety of another molecule to form a covalent linkage.
16. The activated polymer of claim 15 wherein said reactive moiety is a thiol moiety.
17. The activated polymer of claim 1 wherein said active sulfone moiety is linked to said polymer by a linkage that includes a linker moiety and wherein said polymer includes an active moiety other than said active sulfone moiety for linking to said linker moiety.
18. The activated polymer of claim 17 wherein said other active moiety is capable of reacting with an amino group to form a covalent linkage and said linker moiety includes an active amine moiety.
19. The activated polymer of claim 17 wherein said activated polymer is poly(ethylene glycol), said other active moiety is an amino moiety, said linker has the structure NHS-O2C-CH2-CH2-SO2-CH=CH2, and said activated polymer has the structure PEG-NH-CO-CH2-CH2-SO2-CH=CH2.
20. The activated polymer of claim 1 wherein said activated polymer is stable in aqueous environments of pH 11 or less.
21. The activated polymer of claim 1 wherein said activated polymer is selective for reaction with thiol moieties at pH
conditions of about 9 or less.
conditions of about 9 or less.
22. the activated polymer of claim 1 wherein said activated polymer is stable in most reducing environments.
23. The activated polymer of claim 1 wherein said activated polymer is infinitely soluble in water.
24. An activated poly(ethylene glycol) derivative having the structure:
R-CH2CH2- (OCH2CH2) n-Y
wherein n equals 5 to 3,000; Y is -S0 2-CH2-CH2-X, where a second carbon atom is the second carbon atom from the sulfone group (S0 2), X is halogen, end derivatives thereof; and wherein R is selected from the group consisting of HO-, H3CO-, CH2=CH-SO2-, X-CH2CH2-S0 2-, and derivatives thereof, or a poly(ethylene glycol) activating moiety other than CH2=CH-SO; or X-CH2 CH2-S0 2- and derivatives thereof with the provision that the thiol specific reactivtty of the reactive site an the second carbon and the water solubility of the poly(ethylene glycol) derivative is maintained.
R-CH2CH2- (OCH2CH2) n-Y
wherein n equals 5 to 3,000; Y is -S0 2-CH2-CH2-X, where a second carbon atom is the second carbon atom from the sulfone group (S0 2), X is halogen, end derivatives thereof; and wherein R is selected from the group consisting of HO-, H3CO-, CH2=CH-SO2-, X-CH2CH2-S0 2-, and derivatives thereof, or a poly(ethylene glycol) activating moiety other than CH2=CH-SO; or X-CH2 CH2-S0 2- and derivatives thereof with the provision that the thiol specific reactivtty of the reactive site an the second carbon and the water solubility of the poly(ethylene glycol) derivative is maintained.
25. The activated poly(ethylene glycol) derivative of claim 24 wherein n equals about 5 t0 2200.
26. The activated poly(ethylene glycol) derivative of claim 24 wherein n equals about 34 to 1100.
27. The activated poly(ethylene glycol) derivative of claim 24 wherein n equals about 45 to 110.
28. A hydrolytically stable, biologically active conjugate comprises a biologically active molecule having a reactive thiol moiety and a water-soluble polymer derivative having an active sulfone moiety forming a tintcage with said thiol moiety, wherein said conjugate being suitable far in vivo administration.
29. The conjugate of claim 28 wherein said biologically active molecule is a protein and said reactive thiol moiety is contained within a cysteine moiety of said protein.
30. The conjugate of claim 28 wherein said polymer derivative is hydrolytically stable and is selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefnic alcohols).
31. The conjugate of claim 28 wherein said conjugate has the following structure:
PEG-SO2-CH2-CH2-S-W, where W is a biologically active molecule.
PEG-SO2-CH2-CH2-S-W, where W is a biologically active molecule.
32. A hydrolytically stable, biologically active conjugate comprising:
two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety; and a water-soluble: dumbbell polymer derivative having a reactive moiety at each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said reactive moieties on said polymer, wherein said active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety; and a water-soluble: dumbbell polymer derivative having a reactive moiety at each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said reactive moieties on said polymer, wherein said active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
33. The conjugate of claim 32 wherein said biologically active moieties are selected from the group consisting of proteins, pharmaceuticals, cells, vitamins, and combinations thereof.
34. The conjugate of claim 32 wherein said active sulfone moiety is vinyl sulfone or haloethyl sulfone and said other reactive moiety on said polymer derivative is selective for reaction with amino groups.
35. A biologically active conjugate comprising:
an activated water soluble polymer having at least one active sulfone moiety that is selective for reaction with thiol moieties, and at least one other moiety that is selective for reaction with amino moieties, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
an activated water soluble polymer having at least one active sulfone moiety that is selective for reaction with thiol moieties, and at least one other moiety that is selective for reaction with amino moieties, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
36. The conjugate of claim 35 wherein said first protein contains cysteine units and said second protein contains lysine units.
37. A biomaterial comprising a surface and at least one water-soluble polymer derivative linked to said surface through a polymer activating group and having at least one active sulfone moiety on the opposite terminus of said polymer derivative, said polymer derivative comprising a polymer selected from the group consisting of poly (alkylene oxides), poly (oxyethylated polyols), and poly (olefinic alcohols), wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molucule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone goup for reaction with said polymer to form an ester or amide linkage with said polymer derivative.
38. The biomaterial of claim 37 wherein said surface has at least one reactive moiety on the surface and said polymer derivative is a heterobifunctional dumbbell structure having a moiety on one terminus that is linked to said reactive moiety on said surface, said dumbbell having an active sulfone moiety located on the opposite terminus.
39. The biomateriai of claim 38 wherein said reactive moiety is an amine moiety and said moiety of said polymer derivative that is linked with said amine moiety is an amine-selective moiety.
40. The biomaterial of claim 37 wherein said active sulfone moiety is selected from the group consisting of vinyl sulfone, active ethyl sulfone, and derivatives thereof.
41. The biomaterial of claim 37 wherein said polymer derivative comprise: a PEG polymer.
42. A method for synthesizing an isolatable water soluble activated organic polymer having an active sulfone moiety wherein the linkage between the polymer and the sulfone moiety is stable against hydrolysis, the method comprising the steps of linking a sulfur containing moiety to a carbon atom of the polymer and then converting the sulfur containing moiety to an active sulfone moiety.
43. The method of claim 42 further comprising the step of isolating the activated polymer having the active sulfone moiety.
44. The method of claim 42 wherein said step of linking a sulfur containing moiety directly to a carbon atom of the polymer comprises the steps of activating at least one activatable hydroxyl moiety on the polymer and reacting the resulting compound with an alcohol containing a thiol moiety to cause sulfur to be linked directly to the carbon-carbon chain of the polymer.
45. The method of claim 44 wherein said step of activating at least one activatable hydroxyl moiety is selected from the steps consisting of hydroxyl substitution and replacement of hydroxyl hydrogen with a more reactive moiety.
46. The method of claim 44 wherein the alcohol containing a thiol moiety is mercaptoethanol.
47. The method of claim 44 wherein the alcohol containing the thiol moiety is converted to an active sulfone moiety by the steps of oxidizing the sulfur in the sulfur containing moiety to sulfone and reacting the product with a hydroxyl activating or substituting moiety.
48. The method of claim 46 wherein the sulfone is an active ethyl sulfone and the method further comprises the step of forming a vinyl sulfone moiety on the polymer by reacting the active ethyl sulfone with a strong base.
49. A method for preparing isolatable poly(ethylene glycol) vinyl sulfone comprising the steps of:
(a) reacting poly(ethylene glycol) having at least one active hydroxyl moiety with a compound to form either an ester or a halide substituted poly(ethylene glycol);
(b) reacting the ester or a halide substituted poly(ethylene glycol) of step (a) with mercaptoethanol to substitute the mercaptoethanol radical for the ester or halide moiety;
(c) reacting the mercaptoethanol substituted poly(ethylene glycol) of step (b) with an oxidizing agent to oxidize sulfur in the mercaptoethanol moiety to sulfone;
(d) reacting the sulfone of step (c) with a compound to convert the hydroxyl of the mercaptoethanol moiety to an ester or halide moiety;
(e) reacting the ethyl sulfone of step (d) with base to form poly(ethylene glycol) vinyl sulfone.
(a) reacting poly(ethylene glycol) having at least one active hydroxyl moiety with a compound to form either an ester or a halide substituted poly(ethylene glycol);
(b) reacting the ester or a halide substituted poly(ethylene glycol) of step (a) with mercaptoethanol to substitute the mercaptoethanol radical for the ester or halide moiety;
(c) reacting the mercaptoethanol substituted poly(ethylene glycol) of step (b) with an oxidizing agent to oxidize sulfur in the mercaptoethanol moiety to sulfone;
(d) reacting the sulfone of step (c) with a compound to convert the hydroxyl of the mercaptoethanol moiety to an ester or halide moiety;
(e) reacting the ethyl sulfone of step (d) with base to form poly(ethylene glycol) vinyl sulfone.
50. The method of claim 49 further comprising the steps of isolating the poly(ethylene glycol) vinyl sulfone.
51. The method of claim 49 wherein the halide of step (d) is chlorine and the product of step (d) is poly(ethylene glycol) chloroethyl sulfone, and wherein the method further comprises the step of isolating the poly(ethylene glycol) chloroethyl sulfone by dissolving the chloroethyl sulfone in dichloromethane, precipitating the chloroethyl sulfone in ethyl ether, and recrystallizing the precipitate from ethyl acetate.
52. The method of claim 51 further comprising the steps of dissolving the poly(ethylene glycol) chloroethyl sulfone crystals in an organic solvent prior to reaction with base to form poly(ethylene glycol) vinyl sulfone, and isolating the poly(ethylene glycol) vinyl sulfone product by filtering to remove the base and evaporating the solvent.
53. A method for synthesizing a hydrolytically stable water soluble activated polymer having an active sulfone moiety, the method comprising the step of attaching a linking moiety containing an active sulfone moiety and a different active moiety to a polymer derivative selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) having a functional group other than a sulfone moiety and wherein the functional group is selective for the other active moiety on said linker moiety.
54. The method of claim 53 wherein the functional group on said polymer derivative is selective for reaction with amino moieties and the other active moiety on the linker moiety contains an active amino moiety.
55. The method of claim 53 wherein the polymer derivative is PEG succinimidyl active ester and the linker moiety has the structure NH2-CH2-CH2-SO2-CH=CH2.
56. The method of claim 53 further comprising the steps of preparing a polymer derivative selected from the group consisting of polyethylene glycol), polypropylene glycol), poly(oxyethylated glycerol), poly(oxyethylated sorbitol), poly(oxyethylated glucose), and polyvinyl alcohol) having a functional group that is selective for amino moieties;
preparing a linker moiety that contains an amino moiety and a sulfone moiety; and linking the amino moiety on the linker moiety to the amino selective moiety on the polymer derivative.
preparing a linker moiety that contains an amino moiety and a sulfone moiety; and linking the amino moiety on the linker moiety to the amino selective moiety on the polymer derivative.
57. A method for preparing a conjugate of a substance comprising an active thiol moiety and a water soluble activated polymer selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols) having at least one sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage, said method comprising the steps of reacting the substance with the activated polymer having a active sulfone moiety and forming a linkage between the thiol moiety and the sulfone moiety.
58. The method of claim 57 wherein the substance includes an active amino moiety, the polymer derivative includes an amino-selective moiety, and the linkage is formed between the amino moiety and the amino selective moiety.
59. The method of claim 57 wherein the activated polymer is selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), poly(oxyethylated glycerol), poly(oxyethylated sorbitol), poly(oxyethylated glucose), and poly(vinyl alcohol).
60. The method of claim 57 wherein said substance is selected from the group consisting of synthetics for biomaterials, proteins, pharmaceuticals, cells, and vitamins.
61. A method for preparing a conjugate of a biologically active molecule and an active derivative of polyethylene glycol), said method comprising the steps of reacting a biologically active molecule having a reactive thiol moiety with a poly(ethylene glycol) derivative having an active sulfone moiety and forming a linkage between the thiol moiety and the active sulfone moiety, wherein said at least one active sulfone moiety is an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
62. The method of claim 61 wherein said step of reacting a biologically active molecule with a polyethylene glycol) derivative is performed at conditions of pH of less than about 11.
63. The method of claim 61 wherein said step of reacting a biologically active molecule with a poly(ethylene glycol) derivative is performed at a pH of about 9 or less.
64. The method of claim 61 wherein the active sulfone moiety is selected from the group consisting of vinyl sulfone, active ethyl sulfone, and active derivatives thereof.
65. An activated poly(ethylene glycol) derivative having the structure:
CH3-(OCH2CH3)n-SO2-CH=CH2 wherein n equals 5 to 3,000, wherein the vinyl sulfone moiety is derived from an active ethyl sulfone group.
CH3-(OCH2CH3)n-SO2-CH=CH2 wherein n equals 5 to 3,000, wherein the vinyl sulfone moiety is derived from an active ethyl sulfone group.
66. An activated poly(ethylene glycol) derivative having the structure:
CH2=CH-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH=CH2 wherein n equals 5 to 3,000 wherein the vinyl sulfone moieties are derived from an active ethyl sulfone group.
CH2=CH-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH=CH2 wherein n equals 5 to 3,000 wherein the vinyl sulfone moieties are derived from an active ethyl sulfone group.
67. A hydrolytically stable, biologically active conjugate that is the reaction product of 1) at least one biologically active molecule having the structure W-SH, wherein W- is a biologically active moiety and -SH is a reactive thiol moiety, and 2) a poly(ethylene glycol) derivative activated with one or more sulfone moieties and having the structure:
R-CH2-CH2-(OCH2CH2)n-Y
wherein n equals 5 to 3,000, Y is -SO2-CH=CH2, and R is X-CH2-CH2-SO2-, wherein X is halogen, and wherein said reactive thiol moiety is linked to said at least one active sulfone moiety.
R-CH2-CH2-(OCH2CH2)n-Y
wherein n equals 5 to 3,000, Y is -SO2-CH=CH2, and R is X-CH2-CH2-SO2-, wherein X is halogen, and wherein said reactive thiol moiety is linked to said at least one active sulfone moiety.
68. The conjugate of claim 67 wherein said biologically active molecule is protein and said reactive thiol moiety is contained within a cysteine moiety of said protein.
69. The conjugate of claim 68 wherein said conjugate has the following structure:
R-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-W
wherein n equals 5 to 3,000 and R is selected from the group consisting of HO- and H3CO-.
R-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-W
wherein n equals 5 to 3,000 and R is selected from the group consisting of HO- and H3CO-.
70. The biologically active conjugate of claim 68 wherein said conjugate has the following structure:
W-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-W
wherein n equals 5 to 3,000.
W-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-W
wherein n equals 5 to 3,000.
71. The biologically active conjugate of claim 68 wherein said conjugate has the following structure:
R-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein wherein n equals 5 to 3,000 and R is selected from the group consisting of HO- and H3CO-.
R-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein wherein n equals 5 to 3,000 and R is selected from the group consisting of HO- and H3CO-.
72. The biologically active conjugate of claim 68 wherein said conjugate has the following structure:
protein-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein wherein n equals 5 to 3,000.
protein-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein wherein n equals 5 to 3,000.
73. A method for preparing a biologically active conjugate of at least one biologically active molecule having the structure W-SH, wherein W- is a biologically active moiety and -SH is an active thiol moiety, and an activated poly(ethylene glycol) derivative having at least one active sulfone moiety, the activated poly(ethylene glycol) derivative having the structure R-CH2CH2-(OCH2CH2)n-Y, wherein n equals 5 to 3,000, Y is SO2-CH=CH2, and R is X-CH2-CH2-SO2-, wherein X is halogen, said method comprising the steps of reacting the biologically active molecule with the activated poly(ethylene glycol) derivative and forming a linkage between the active thiol moiety and the at least one active sulfone moiety of the poly(ethylene glycol).
74. The method of claim 74 wherein W is protein.
75. A method of preparing a biologically active conjugate having the structure:
protein-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein, wherein n equals 5 to 3,000, the method comprising the steps of 1) reactivating at least one protein having an active thiol moiety with a sulfone activated poly(ethylene glycol) derivative having the structure R-CH2CH2-(OCH2CH2)n-SO2-CH=CH2, wherein R is X-CH2-CH2-SO2, wherein n equals 5 to 3,000, and wherein X is halogen, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moieties of the activated polymer.
protein-S-CH2-CH2-SO2-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein, wherein n equals 5 to 3,000, the method comprising the steps of 1) reactivating at least one protein having an active thiol moiety with a sulfone activated poly(ethylene glycol) derivative having the structure R-CH2CH2-(OCH2CH2)n-SO2-CH=CH2, wherein R is X-CH2-CH2-SO2, wherein n equals 5 to 3,000, and wherein X is halogen, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moieties of the activated polymer.
76. A method for preparing a biologically active conjugate having the structure H3CO-CH2-CH2-(OCH2CH2)n-SO2-CH2-CH2-S-protein wherein n equals 5 to 3,000, the method comprising the steps of 1) reacting a protein having an active thiol moiety with an activated poly(ethylene glycol) derivative having the structure H3 CO-CH2-CH2-(OCH2CH2)n-SO2-CH=CH2, wherein n equals to 3,000, and 2) forming a linkage between the active thiol moiety of the protein and the active sulfone moiety of the activated polymer.
77. A pharmaceutical composition comprising a hydrolytically stable, biologically active conjugate, said conjugate comprising of:
a biologically active molecule having a reactive thiol moiety or amino moiety; and a water-soluble polymer derivative having an active sulfone moiety forming a covalent linkage with said thiol moiety or amino moiety.
a biologically active molecule having a reactive thiol moiety or amino moiety; and a water-soluble polymer derivative having an active sulfone moiety forming a covalent linkage with said thiol moiety or amino moiety.
78. The pharmaceutical composition of claim 77, wherein said polymer derivative comprises poly(ethylene glycol).
79. The pharmaceutical composition of claim 77, wherein said active sulfone moiety is a vinyl sulfone, an active ethyl sulfone, or is derived from a molecule having a vinyl sulfone group and a non-vinyl active group linked to the vinyl sulfone group for reaction with said polymer to form an ester or amide linkage.
80. The activated polymer of Claim 1, wherein said non-vinyl active group is selected from the group consisting of NHS-O2C-(CH2)- and H2N-(CH2)-.
81. A water soluble hydrolytically stable activated polymer comprising at least one active sulfone moiety covalently linked to a polymer selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), and poly(olefinic alcohols), wherein said at least one active sulfone moiety is a vinyl sulfone derived from an active ethyl sulfone group linked to said polymer.
82. An activated poly(ethylene glycol) derivative having the structure:
R-CH2CH2-(OCH2CH2)n-Y
wherein n equals 5 to 3,000; Y is selected from the group consisting of -SO2-CH=CH2 derived from an active ethyl sulfone group, -SO2-CH2-CH2-X, where X is halogen, and derivatives thereof; and wherein R is selected from the group consisting of HO-, H3CO-, CH2=CH-SO2-, X-CH2-CH2-SO2-, and derivatives thereof, or a poly(ethylene glycol) activating moiety other than CH2=CH-SO2- or X-CH2-CH2-SO2-and derivatives thereof with the provision that the thiol specific reactivity of the reactive site on the second carbon and the water solubility of the poly (ethylene glycol] derivative is maintained.
R-CH2CH2-(OCH2CH2)n-Y
wherein n equals 5 to 3,000; Y is selected from the group consisting of -SO2-CH=CH2 derived from an active ethyl sulfone group, -SO2-CH2-CH2-X, where X is halogen, and derivatives thereof; and wherein R is selected from the group consisting of HO-, H3CO-, CH2=CH-SO2-, X-CH2-CH2-SO2-, and derivatives thereof, or a poly(ethylene glycol) activating moiety other than CH2=CH-SO2- or X-CH2-CH2-SO2-and derivatives thereof with the provision that the thiol specific reactivity of the reactive site on the second carbon and the water solubility of the poly (ethylene glycol] derivative is maintained.
83. A hydrolytically stable, biologically active conjugate comprises of:
two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety;
and a water-soluble dumbbell polymer derivative having a reactive moiety at each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said reactive moieties on said polymer, wherein said active sulfone moiety is a vinyl sulfone derived from an active ethyl sulfone group linked to said polymer.
two biologically active moieties, which may be the same or different, at least one of said biologically active moieties having a reactive thiol moiety;
and a water-soluble dumbbell polymer derivative having a reactive moiety at each terminal end thereof, at least one of said reactive moieties being an active sulfone moiety and forming a linkage with said thiol moiety of said at least one biologically active moiety, the other of said biologically active moieties forming a linkage with the other of said reactive moieties on said polymer, wherein said active sulfone moiety is a vinyl sulfone derived from an active ethyl sulfone group linked to said polymer.
84. A biologically active conjugate comprises:
an activated water soluble polymer having at least one active sulfone moiety that is selective for reaction with thiol moieties, and at least one other moiety that is selective for reaction with amino moieties, wherein said at least active sulfone moiety is a vinyl sulfone derived from an active ethyl sulfone group linked to said polymer;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
an activated water soluble polymer having at least one active sulfone moiety that is selective for reaction with thiol moieties, and at least one other moiety that is selective for reaction with amino moieties, wherein said at least active sulfone moiety is a vinyl sulfone derived from an active ethyl sulfone group linked to said polymer;
a first protein having a thiol moiety wherein said thiol moiety forms a hydrolytically stable linkage with said sulfone moiety on said polymer; and a second protein having an amino moiety wherein said amino moiety forms a linkage with said other moiety on said polymer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US151,481 | 1993-11-12 | ||
| US08/151,481 US5446090A (en) | 1993-11-12 | 1993-11-12 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| PCT/US1994/013013 WO1995013312A1 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2176203A1 CA2176203A1 (en) | 1995-05-18 |
| CA2176203C true CA2176203C (en) | 2003-06-10 |
Family
ID=22538958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002176203A Expired - Fee Related CA2176203C (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US5446090A (en) |
| EP (2) | EP0728155B1 (en) |
| JP (1) | JP3114998B2 (en) |
| KR (1) | KR100225746B1 (en) |
| CN (1) | CN1085689C (en) |
| AT (1) | ATE215577T1 (en) |
| AU (1) | AU687937B2 (en) |
| BG (1) | BG63399B1 (en) |
| BR (1) | BR9408048A (en) |
| CA (1) | CA2176203C (en) |
| CZ (1) | CZ295640B6 (en) |
| DE (1) | DE69430317T2 (en) |
| DK (1) | DK0728155T3 (en) |
| EE (1) | EE03448B1 (en) |
| ES (1) | ES2173943T3 (en) |
| FI (1) | FI117441B (en) |
| HK (1) | HK1042312A1 (en) |
| HU (1) | HU225649B1 (en) |
| NO (1) | NO315377B1 (en) |
| NZ (1) | NZ276313A (en) |
| PL (1) | PL180149B1 (en) |
| RO (2) | RO121855B1 (en) |
| RU (1) | RU2176253C2 (en) |
| SK (1) | SK284527B6 (en) |
| UA (1) | UA58481C2 (en) |
| WO (1) | WO1995013312A1 (en) |
Families Citing this family (440)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20010055581A1 (en) | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
| US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| CN1215340A (en) | 1996-02-09 | 1999-04-28 | 安姆根有限公司 | Composition comprising interleukin-1 inhibitor and controlled release polymer |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| AU4648697A (en) * | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
| US8003705B2 (en) * | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
| DE69713517D1 (en) * | 1996-10-15 | 2002-07-25 | Medical Analysis Systems Inc | Process for the stabilization of troponin I (CTnI) by conjugation with an active polymer |
| EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
| AU5696198A (en) | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| US6743248B2 (en) | 1996-12-18 | 2004-06-01 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| US20040176801A1 (en) * | 1997-03-12 | 2004-09-09 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| US20030191496A1 (en) * | 1997-03-12 | 2003-10-09 | Neomend, Inc. | Vascular sealing device with microwave antenna |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| WO1998051336A1 (en) * | 1997-05-15 | 1998-11-19 | Theratech, Inc. | Targeted delivery to t lymphocytes |
| US6284246B1 (en) | 1997-07-30 | 2001-09-04 | The Procter & Gamble Co. | Modified polypeptides with high activity and reduced allergenicity |
| US6251866B1 (en) | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
| US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
| US6129928A (en) * | 1997-09-05 | 2000-10-10 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
| US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US6066673A (en) * | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
| ES2307865T3 (en) * | 1998-03-12 | 2008-12-01 | Nektar Therapeutics Al, Corporation | METHOD FOR PREPARING POLYMERIC CONJUGATES. |
| JP2002507426A (en) | 1998-03-26 | 2002-03-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | Serine protease variants with amino acid substitutions |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| US6495136B1 (en) | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
| US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
| US6994686B2 (en) * | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
| DE69914611T2 (en) * | 1998-08-28 | 2004-12-23 | Gryphon Therapeutics, Inc., South San Francisco | METHOD FOR PRODUCING POLYAMIDE CHAINS OF EXACT LENGTH AND THEIR CONJUGATES WITH PROTEINS |
| US6551613B1 (en) * | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
| EP1115366A2 (en) | 1998-09-22 | 2001-07-18 | The Procter & Gamble Company | Personal care compositions containing active proteins tethered to a water insoluble substrate |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6899889B1 (en) * | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
| US7279001B2 (en) * | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6830756B2 (en) | 1998-11-06 | 2004-12-14 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6949114B2 (en) | 1998-11-06 | 2005-09-27 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| JP2002531217A (en) * | 1998-12-04 | 2002-09-24 | チャンドラシェカー ピー． パサック， | Biocompatible crosslinked polymer |
| US6958212B1 (en) * | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| ES2368988T3 (en) | 1999-02-01 | 2011-11-24 | Eidgenössische Technische Hochschule Zürich | BIO-MATERIALS FORMED BY REACTION OF NUCLEPHILE ADDITION TO CONJUGATED INSATURATED GROUPS. |
| WO2000078285A1 (en) * | 1999-06-18 | 2000-12-28 | University Of Medicine And Dentistry Of New Jersey | Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
| EP1210415A2 (en) | 1999-07-22 | 2002-06-05 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
| MXPA02000842A (en) | 1999-07-22 | 2002-07-30 | Procter & Gamble | Protease conjugates having sterically protected clip sites. |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| BR0012693A (en) | 1999-07-22 | 2002-04-09 | Procter & Gamble | Variant, of subtilisin-like protease; cleaning composition; and personal care composition |
| US7008635B1 (en) | 1999-09-10 | 2006-03-07 | Genzyme Corporation | Hydrogels for orthopedic repair |
| US6303119B1 (en) | 1999-09-22 | 2001-10-16 | The Procter & Gamble Company | Personal care compositions containing subtilisin enzymes bound to water insoluble substrates |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US7074878B1 (en) * | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| ES2327606T3 (en) | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | CONJUGATES OF G-CSF. |
| ES2325877T3 (en) | 2000-02-11 | 2009-09-23 | Bayer Healthcare Llc | FACTOR TYPE MOLECULES VII OR VIIA. |
| WO2001087487A2 (en) | 2000-05-15 | 2001-11-22 | Tecan Trading Ag | Bidirectional flow centrifugal microfluidic devices |
| CN1318443C (en) * | 2000-05-16 | 2007-05-30 | 博尔德生物技术公司 | Methods for refolding proteins containing free cysteine residues |
| US7291673B2 (en) * | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| MXPA03000311A (en) * | 2000-07-12 | 2004-12-13 | Gryphon Therapeutics Inc | Chemokine receptor modulators, production and use. |
| US7030218B2 (en) * | 2000-09-08 | 2006-04-18 | Gryphon Therapeutics | Pseudo native chemical ligation |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| EP1355965B1 (en) * | 2000-10-19 | 2012-09-19 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method of synthesizing block copolymers for multifunctional self-assembled systems |
| ES2382636T3 (en) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Method for producing compositions for improved administration of bioactive molecules |
| TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| WO2002074806A2 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
| CA2440844A1 (en) * | 2001-03-20 | 2002-09-26 | Universitat Zurich | Two-phase processing of thermosensitive polymers for use as biomaterials |
| US6538104B2 (en) * | 2001-04-27 | 2003-03-25 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
| US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| ATE376020T1 (en) * | 2001-08-22 | 2007-11-15 | Bioartificial Gel Technologies Inc | METHOD FOR PRODUCING ACTIVATED POLYETHYLENE GLYCOLS |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| DK2279755T3 (en) | 2001-10-10 | 2014-05-26 | Ratiopharm Gmbh | Remodeling and glycoconjugation of fibroblast growth factor (FGF) |
| ES2606840T3 (en) | 2001-10-10 | 2017-03-28 | Ratiopharm Gmbh | Remodeling and glycoconjugation of granulocyte colony stimulating factor (G-CSF) |
| SI1436012T1 (en) | 2001-10-18 | 2018-03-30 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
| US8013134B2 (en) * | 2001-11-23 | 2011-09-06 | Olink Ab | Kit for proximity probing with multivalent proximity probes |
| MEP35608A (en) | 2002-01-18 | 2011-02-10 | Biogen Idec Inc | Polyalkylene polymer compounds and uses thereof |
| US20030179692A1 (en) * | 2002-03-19 | 2003-09-25 | Yoshitaka Ohotomo | Storage medium |
| US8282912B2 (en) * | 2002-03-22 | 2012-10-09 | Kuros Biosurgery, AG | Compositions for tissue augmentation |
| JP2005534647A (en) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | Prevention and reduction of blood loss |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| CA2490360A1 (en) | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
| MXPA04012496A (en) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Pegylated factor vii glycoforms. |
| US7034127B2 (en) * | 2002-07-02 | 2006-04-25 | Genzyme Corporation | Hydrophilic biopolymer-drug conjugates, their preparation and use |
| AU2003270341A1 (en) * | 2002-09-05 | 2004-03-29 | The General Hospital Corporation | Modified asialo-interferons and uses thereof |
| JP2006510589A (en) * | 2002-09-05 | 2006-03-30 | ザ ジェネラル ホスピタル コーポレーション | Treatment of asialointerferon and liver cancer |
| CA2497980C (en) | 2002-09-09 | 2011-06-21 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| CN1312279C (en) * | 2002-11-07 | 2007-04-25 | 连云港新阳医药有限公司 | Method for preparing elspar modilfied by carbowax |
| GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| EP1616003A4 (en) | 2002-12-30 | 2007-06-20 | Gryphon Therapeutics Inc | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| ES2352337T5 (en) * | 2003-01-06 | 2017-08-11 | Nektar Therapeutics | Thiol-selective derivatives of a water soluble polymer |
| US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| CA2509939C (en) * | 2003-01-06 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polymer derivatives |
| HUE058897T2 (en) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| BRPI0408116B1 (en) * | 2003-03-05 | 2022-09-20 | Halozyme, Inc | POLYMER-CONJUGATED SOLUBLE HYALURONIDASE POLYPEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SOLUBLE PH20 POLYPEPTIDES, THEIR USES AND PREPARATION PROCESS, AND NUCLEIC ACIDS ENCODING SOLUBLE HYALURONIDASE POLYPEPTIDES |
| CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US7587286B2 (en) * | 2003-03-31 | 2009-09-08 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| CA2521381C (en) | 2003-04-11 | 2020-05-26 | Kenneth Hinds | Method for preparation of site-specific protein conjugates |
| EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
| BRPI0410164A (en) | 2003-05-09 | 2006-05-16 | Neose Technologies Inc | compositions and methods for preparing human growth hormone glycosylation mutants |
| US20040249119A1 (en) * | 2003-06-05 | 2004-12-09 | Fox Martin Edward | Novel mPEG propionaldehyde precursor |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| CA2533702C (en) | 2003-07-22 | 2012-05-22 | Nektar Therapeutics Al, Corporation | Method for preparing functionalized polymers from polymer alcohols |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| CA2536873C (en) * | 2003-08-29 | 2019-09-10 | Dyax Corp. | Poly-pegylated protease inhibitors |
| CN1852740B (en) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | Multi-arm polymer prodrugs |
| ES2737837T3 (en) * | 2003-10-09 | 2020-01-16 | Ambrx Inc | Polymeric derivatives |
| WO2005035564A2 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US7524813B2 (en) * | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| WO2005035565A1 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Il-21 derivatives |
| EP2641611A3 (en) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| EP1725572B1 (en) | 2003-11-05 | 2017-05-31 | AGCT GmbH | Macromolecular nucleotide compounds and methods for using the same |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| ES2445948T3 (en) * | 2003-11-24 | 2014-03-06 | Ratiopharm Gmbh | Glycopegylated Erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| AU2004311630A1 (en) | 2003-12-02 | 2005-07-21 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| ES2560657T3 (en) | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | O-linked glycosylation of G-CSF peptides |
| CA2554755A1 (en) * | 2004-01-28 | 2005-08-11 | Cytimmune Sciences, Inc. | Functionalized colloidal metal compositions and methods |
| BRPI0507169A (en) * | 2004-02-02 | 2007-06-26 | Ambrx Inc | modified human growth hormone polypeptides and their uses |
| KR100580644B1 (en) * | 2004-02-16 | 2006-05-16 | 삼성전자주식회사 | A method for noncovalently immobilizing a biomolecule on a solid substrate and a microarray produced by the same |
| US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
| US9446139B2 (en) * | 2004-03-15 | 2016-09-20 | Nektar Therapeutics | Polymer-based compositions and conjugates of HIV entry inhibitors |
| CA2557782A1 (en) * | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| US8470315B2 (en) * | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| JP2008503217A (en) * | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | Novel antigen-binding polypeptides and their use |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| JP2008506703A (en) | 2004-07-14 | 2008-03-06 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Netrin-related compounds and uses |
| AU2005327906B2 (en) * | 2004-07-21 | 2010-05-13 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| AU2005286662B2 (en) | 2004-09-23 | 2011-10-06 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| CA2584510C (en) * | 2004-10-25 | 2013-05-28 | Intezyne Technologies, Incorporated | Heterobifunctional poly(ethylene glycol) and uses thereof |
| DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
| CA2591233C (en) | 2004-12-21 | 2014-10-07 | Nektar Therapeutics Al, Corporation | Stabilized polymeric thiol reagents |
| EP1836314B1 (en) | 2004-12-22 | 2012-01-25 | Ambrx, Inc. | Modified human growth hormone |
| JP5425398B2 (en) | 2004-12-22 | 2014-02-26 | アンブレツクス・インコーポレイテツド | Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides |
| NZ555206A (en) | 2004-12-22 | 2010-09-30 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| CA2594561C (en) * | 2004-12-22 | 2014-12-23 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| CA2590429C (en) * | 2004-12-22 | 2014-10-07 | Ambrx, Inc. | Compositions of aminoacyl-trna synthetase and uses thereof |
| JP4951527B2 (en) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | GlycoPEGylated granulocyte colony stimulating factor |
| US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
| WO2006086510A2 (en) * | 2005-02-09 | 2006-08-17 | Tyco Healthcare Group Lp | Synthetic sealants |
| EP2314320A2 (en) | 2005-04-05 | 2011-04-27 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| WO2006110776A2 (en) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Polyethylene glycol cojugates of antimicrobial agents |
| EP2360181B1 (en) | 2005-04-18 | 2013-09-18 | Novo Nordisk A/S | IL-21 variants |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| KR101011081B1 (en) | 2005-05-13 | 2011-01-25 | 일라이 릴리 앤드 캄파니 | Glp-1 pegylated compounds |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| US9505867B2 (en) * | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| CN103030690A (en) * | 2005-06-03 | 2013-04-10 | Ambrx公司 | Improved human interferon molecules and their uses |
| AU2006259525B2 (en) | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| WO2007011802A1 (en) * | 2005-07-18 | 2007-01-25 | Nektar Therapeutics Al, Corporation | Method for preparing branched functionalized polymers using branched polyol cores |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| ES2408581T3 (en) * | 2005-08-18 | 2013-06-21 | Ambrx, Inc. | TRNA compositions and uses thereof |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| JP5508716B2 (en) * | 2005-11-08 | 2014-06-04 | アンブルックス，インコーポレイテッド | Accelerators for modifying unnatural amino acids and unnatural amino acid polypeptides |
| US20090018029A1 (en) * | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
| CA2882445A1 (en) * | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| JP5096363B2 (en) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | GLP-1 polymer complex |
| US7743730B2 (en) * | 2005-12-21 | 2010-06-29 | Lam Research Corporation | Apparatus for an optimized plasma chamber grounded electrode assembly |
| ES2664086T3 (en) | 2005-12-30 | 2018-04-18 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neurregulin to improve cardiac function |
| EP1984009B1 (en) | 2006-01-18 | 2012-10-24 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| EP2319542B1 (en) | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
| JP2009533347A (en) | 2006-04-07 | 2009-09-17 | ネクター セラピューティックス エイエル，コーポレイション | Anti-TNFα antibody complex |
| WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
| US7560588B2 (en) | 2006-04-27 | 2009-07-14 | Intezyne Technologies, Inc. | Poly(ethylene glycol) containing chemically disparate endgroups |
| RU2008145084A (en) | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO |
| EP2044097A4 (en) * | 2006-06-23 | 2010-10-06 | Quintessence Biosciences Inc | Modified ribonucleases |
| WO2008002482A2 (en) * | 2006-06-23 | 2008-01-03 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
| WO2008010991A2 (en) * | 2006-07-17 | 2008-01-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| WO2008011633A2 (en) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| WO2008030614A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
| AU2007292892B9 (en) * | 2006-09-08 | 2013-02-28 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
| JP5840345B2 (en) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| SI2068907T1 (en) | 2006-10-04 | 2018-01-31 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| WO2008088422A2 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| CA2666426A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
| EP3156415A1 (en) | 2006-11-22 | 2017-04-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| CA2669541C (en) | 2006-11-30 | 2014-11-18 | Nektar Therapeutics Al, Corporation | Method for preparing a polymer conjugate |
| ES2618830T3 (en) | 2006-12-08 | 2017-06-22 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against ANGPTL3 |
| US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
| US8293214B2 (en) | 2006-12-19 | 2012-10-23 | Bracco Suisse S.A. | Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds |
| WO2008079677A2 (en) | 2006-12-20 | 2008-07-03 | Arkema Inc. | Polymer encapsulation and/or binding |
| KR101160385B1 (en) | 2007-01-18 | 2012-07-10 | 일라이 릴리 앤드 캄파니 | PEGYLATED Aß FAB |
| PT2118123E (en) | 2007-01-31 | 2016-02-10 | Harvard College | Stabilized p53 peptides and uses thereof |
| EP2111228B1 (en) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
| US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| KR101476472B1 (en) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | Modified fgf-21 polypeptides and their uses |
| CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
| CN101711168B (en) | 2007-04-13 | 2013-05-01 | 库罗斯生物外科股份公司 | Polymeric tissue sealant |
| JP2010525821A (en) * | 2007-05-02 | 2010-07-29 | アンブルックス，インコーポレイテッド | Modified IFN beta polypeptides and their use |
| US8420779B2 (en) * | 2007-05-22 | 2013-04-16 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| MX2009013259A (en) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Improved process for the production of nucleotide sugars. |
| US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| CN101361968B (en) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | Use of interleukin-22 in treating fatty liver |
| EP2177230A4 (en) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| US8067028B2 (en) * | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
| US20090075887A1 (en) * | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| WO2009048909A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
| MX2010004400A (en) | 2007-10-23 | 2010-05-20 | Nektar Therapeutics | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom. |
| US7960145B2 (en) * | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US20090123519A1 (en) * | 2007-11-12 | 2009-05-14 | Surmodics, Inc. | Swellable hydrogel matrix and methods |
| CA2705521A1 (en) * | 2007-11-12 | 2009-05-22 | Intradigm Corporation | Heterobifunctional polyethylene glycol reagents |
| DK2217265T3 (en) | 2007-11-20 | 2017-07-03 | Ambrx Inc | Modified insulin polypeptides and their use |
| CN103694337B (en) | 2008-02-08 | 2016-03-02 | Ambrx公司 | Modified leptin polypeptide and its purposes |
| PL2257311T3 (en) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Conjugated factor viii molecules |
| TWI395593B (en) | 2008-03-06 | 2013-05-11 | Halozyme Inc | In vivo temporal control of activatable matrix-degrading enzymes |
| US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
| WO2009128917A2 (en) | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| PT2268635E (en) | 2008-04-21 | 2015-10-06 | Taigen Biotechnology Co Ltd | Heterocyclic compounds |
| TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
| KR20110008075A (en) * | 2008-05-16 | 2011-01-25 | 넥타르 테라퓨틱스 | Conjugates of a cholinesterase moiety and a polymer |
| JP2011520961A (en) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | Scaffold domain protein based on multivalent fibronectin |
| EP2326349B1 (en) * | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| EP3225248B1 (en) * | 2008-07-23 | 2023-06-07 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| CN102159250B (en) | 2008-08-11 | 2014-08-06 | 尼克塔治疗公司 | Multi-arm polymeric alkanoate conjugates |
| EP2340047A1 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
| WO2010033218A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
| US20110237524A1 (en) * | 2008-09-19 | 2011-09-29 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033227A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
| WO2010033223A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
| EP2334338A2 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| EP2334333A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
| WO2010033221A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
| AU2009296397B2 (en) | 2008-09-26 | 2012-11-08 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
| KR101732054B1 (en) * | 2008-09-26 | 2017-05-02 | 암브룩스, 인코포레이티드 | Non-natural amino acid replication-dependent microorganisms and vaccines |
| JP2012504423A (en) | 2008-10-01 | 2012-02-23 | クインテッセンス バイオサイエンシズ，インコーポレーテッド | Therapeutic ribonuclease |
| WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
| US8927249B2 (en) | 2008-12-09 | 2015-01-06 | Halozyme, Inc. | Extended soluble PH20 polypeptides and uses thereof |
| GB0823309D0 (en) * | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| WO2010080833A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| WO2010080720A2 (en) | 2009-01-12 | 2010-07-15 | Nektar Therapeutics | Conjugates of a lysosomal enzyme moiety and a water soluble polymer |
| JP5890182B2 (en) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | Drug delivery with hydrogel plugs |
| EP2403538B1 (en) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Conjugated proteins and peptides |
| US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| PT2440239T (en) | 2009-06-09 | 2017-10-19 | Prolong Pharmaceuticals Llc | Hemoglobin compositions |
| JP2013501033A (en) | 2009-08-05 | 2013-01-10 | ピエリス アーゲー | Controlled release formulation of lipocalin mutein |
| JP5734985B2 (en) | 2009-09-17 | 2015-06-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | Stable co-formulations of hyaluronidase and immunoglobulin and methods for their use |
| US9315860B2 (en) | 2009-10-26 | 2016-04-19 | Genovoxx Gmbh | Conjugates of nucleotides and method for the application thereof |
| CN102695723A (en) | 2009-10-30 | 2012-09-26 | 中枢神经系统治疗学公司 | Improved neurturin molecules |
| EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
| AR079344A1 (en) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Oxyntomodulin peptide analogue |
| CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| CN102161754B (en) * | 2010-02-13 | 2012-06-13 | 华中科技大学同济医学院附属协和医院 | Functional modification method for branched polyethylene glycol (PEG) derivative |
| JP6148013B2 (en) | 2010-03-05 | 2017-06-14 | リグショスピタレト | Chimera inhibitor molecule of complement activation |
| JP6066900B2 (en) | 2010-04-26 | 2017-01-25 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of cysteinyl tRNA synthetase |
| AU2011248614B2 (en) | 2010-04-27 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| CA2797271C (en) | 2010-04-28 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
| EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| WO2011139854A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
| US9034321B2 (en) | 2010-05-03 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| CN103140233B (en) | 2010-05-03 | 2017-04-05 | Atyr 医药公司 | Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase |
| CN102985103A (en) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| US20120135912A1 (en) | 2010-05-10 | 2012-05-31 | Perseid Therapeutics Llc | Polypeptide inhibitors of vla4 |
| JP6396656B2 (en) | 2010-05-14 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase |
| US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| JP2013533217A (en) | 2010-05-17 | 2013-08-22 | セビックス・インコーポレイテッド | PEGylated C-peptide |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| CN103096913B (en) | 2010-05-27 | 2017-07-18 | Atyr 医药公司 | Treatment, diagnosis and the innovation of antibody compositions related to the protein fragments of glutaminyl tRNA synzyme is found |
| AU2011261486B2 (en) | 2010-06-01 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases |
| JP6116479B2 (en) | 2010-07-12 | 2017-04-19 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase |
| ES2661089T3 (en) | 2010-07-20 | 2018-03-27 | Halozyme Inc. | Methods of treatment or prevention of adverse side effects associated with the administration of an anti-hyaluronan agent |
| TWI758885B (en) | 2010-07-30 | 2022-03-21 | 瑞士商愛爾康公司 | Hydrated contact lens |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| DK2605789T3 (en) | 2010-08-17 | 2019-09-16 | Ambrx Inc | MODIFIED RELAXIN POLYPEPTIDES AND APPLICATIONS THEREOF |
| WO2012027611A2 (en) | 2010-08-25 | 2012-03-01 | Atyr Pharma, Inc. | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| CA2817568A1 (en) | 2010-11-12 | 2012-05-18 | The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer | Cancer therapies and diagnostics |
| CA3144697A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| EP2643019B1 (en) | 2010-11-24 | 2019-01-02 | Lexicon Pharmaceuticals, Inc. | Antibodies to notum pectinacetylesterase |
| WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
| EP2654795B1 (en) | 2010-12-21 | 2018-03-07 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| KR102169651B1 (en) | 2011-01-06 | 2020-10-23 | 다이액스 코포레이션 | Plasma kallikrein binding proteins |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| PE20140593A1 (en) | 2011-03-16 | 2014-05-10 | Amgen Inc | POWERFUL AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
| US9592251B2 (en) | 2011-06-16 | 2017-03-14 | The Hong Kong University Of Science And Technology | Multi-vinylsulfone containing molecule |
| WO2012174478A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| CA2839512C (en) | 2011-06-17 | 2018-01-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| AR087020A1 (en) | 2011-07-01 | 2014-02-05 | Bayer Ip Gmbh | RELAXIN FUSION POLIPEPTIDES AND USES OF THE SAME |
| CN103747807B (en) | 2011-07-05 | 2016-12-07 | 比奥阿赛斯技术有限公司 | P97 antibody conjugates and using method |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| JP6162707B2 (en) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | Companion diagnostics for antihyaluronan treatment and methods of use thereof |
| CN104053670A (en) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | Fibronectin binding domains with reduced immunogenicity |
| CA2855770A1 (en) | 2011-11-17 | 2013-05-23 | Cebix Ab | Pegylated c-peptide |
| KR20190090048A (en) | 2011-12-05 | 2019-07-31 | 인셉트, 엘엘씨 | Medical organogel processes and compositions |
| EP2858661B1 (en) | 2011-12-29 | 2020-04-22 | Dana-Farber Cancer Institute, Inc. | Stabilized antiviral fusion helices |
| EP3130347B1 (en) | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| WO2013123432A2 (en) | 2012-02-16 | 2013-08-22 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| BR112014024291B1 (en) | 2012-03-30 | 2022-07-05 | The Board Of Regents Of The University Of Oklahoma | METHOD FOR THE RECOMBINANT PRODUCTION OF A HEPAROSAN POLYMER WITH HIGH MOLECULAR WEIGHT, USE OF SUCH TISSUE ANCREASEMENT POLYMER, ISOLATED POLYNUCLEOTIDE AND COMPOSITION OF BIOLOGICAL MATERIAL COMPRISING SUCH POLYMER |
| WO2013151991A1 (en) | 2012-04-02 | 2013-10-10 | Surmodics, Inc. | Hydrophilic polymeric coatings for medical articles with visualization moiety |
| US9913822B2 (en) | 2012-04-04 | 2018-03-13 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and therapeutic agent |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| KR102172897B1 (en) | 2012-06-08 | 2020-11-02 | 서트로 바이오파마, 인크. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| CA2877573A1 (en) | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
| US9315579B2 (en) | 2012-06-22 | 2016-04-19 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CCR2 |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| US9932565B2 (en) | 2012-07-31 | 2018-04-03 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| PL3584255T3 (en) | 2012-08-31 | 2022-05-16 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| JP2016500058A (en) | 2012-11-12 | 2016-01-07 | レッドウッド バイオサイエンス， インコーポレイテッド | Methods for producing compounds and conjugates |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| CN104870423A (en) | 2012-11-16 | 2015-08-26 | 加利福尼亚大学董事会 | Pictet-spengler ligation for protein chemical modification |
| US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
| EP2935311B1 (en) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
| US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| UY35397A (en) | 2013-03-12 | 2014-10-31 | Amgen Inc | POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7 |
| BR112015022416A2 (en) | 2013-03-13 | 2017-10-24 | Bioasis Technologies Inc | p97 fragments and their uses |
| US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
| AU2014227824B2 (en) | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| CN111423511B (en) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-1 |
| TW201534726A (en) | 2013-07-03 | 2015-09-16 | Halozyme Inc | Thermally stable PH20 hyaluronidase variants and uses thereof |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015013510A1 (en) | 2013-07-25 | 2015-01-29 | Ecole Polytechnique Federale De Lausanne Epfl | High aspect ratio nanofibril materials |
| AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
| EP3988992A1 (en) | 2013-11-15 | 2022-04-27 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| JP6745218B2 (en) | 2013-11-27 | 2020-08-26 | レッドウッド バイオサイエンス， インコーポレイテッド | Methods for producing hydrazinyl-pyrrolo compounds and conjugates |
| CN105934257B (en) | 2013-12-06 | 2020-10-09 | 韩捷 | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| MA39711A (en) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugates of an il-15 moiety and a polymer |
| JP7059003B2 (en) | 2014-05-14 | 2022-04-25 | トラスティーズ・オブ・ダートマス・カレッジ | Deimmunized lysostaphin and how to use |
| CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| JP6800141B2 (en) | 2014-08-12 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | Synergistic tumor treatment with IL-2 and integrin-binding FC fusion protein |
| AU2015305894A1 (en) | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR3 |
| PL3186281T3 (en) | 2014-08-28 | 2019-10-31 | Halozyme Inc | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| CN106794259B (en) | 2014-10-14 | 2021-07-16 | 宝力泰锐克斯有限公司 | Method of conjugating peptides or proteins using an agent comprising a leaving group comprising a PEG moiety |
| BR112017007765B1 (en) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME |
| AU2015334717B2 (en) * | 2014-10-24 | 2021-02-25 | Polytherics Limited | Conjugates and conjugating reagents |
| UY36370A (en) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| US10525170B2 (en) * | 2014-12-09 | 2020-01-07 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
| EP3270945A4 (en) | 2015-03-18 | 2018-09-05 | Massachusetts Institute of Technology | Selective mcl-1 binding peptides |
| MX2017016251A (en) | 2015-07-02 | 2018-04-20 | Dana Farber Cancer Inst Inc | Stabilized anti-microbial peptides. |
| US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
| WO2017100679A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN116333124A (en) | 2016-01-29 | 2023-06-27 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-L1 |
| CA3014442A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
| CN109328069B (en) | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Use of IL-22 in the treatment of necrotizing enterocolitis |
| US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
| CN109562167A (en) | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | Combination therapy |
| US11466064B2 (en) | 2016-08-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| ES2963839T3 (en) | 2017-02-08 | 2024-04-02 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
| WO2018172503A2 (en) | 2017-03-24 | 2018-09-27 | Basf Se | Liquid laundry detergent comprising modified saccharide or polysaccharide |
| CA3177086A1 (en) | 2017-06-22 | 2018-12-27 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| AU2018304230A1 (en) | 2017-07-19 | 2020-02-06 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
| EP3688007A1 (en) | 2017-09-27 | 2020-08-05 | The University of York | Bioconjugation of polypeptides |
| EP3724216A1 (en) | 2017-12-15 | 2020-10-21 | Dana Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| CN111094462A (en) | 2017-12-26 | 2020-05-01 | 贝克顿·迪金森公司 | Deep ultraviolet excitable water-solvated polymer dyes |
| AU2019218786A1 (en) | 2018-02-07 | 2020-07-30 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| EP3765852A1 (en) | 2018-03-14 | 2021-01-20 | Dana Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
| WO2019191482A1 (en) | 2018-03-30 | 2019-10-03 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| KR102167755B1 (en) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | Fragmented GRS polypeptide, mutants thereof and use thereof |
| EP3813867A1 (en) | 2018-07-22 | 2021-05-05 | Bioasis Technologies Inc. | Treatment of lymmphatic metastases |
| CN111417655A (en) | 2018-08-28 | 2020-07-14 | 润俊(中国)有限公司 | anti-CD3 antibody folate bioconjugates and uses thereof |
| JP7441826B2 (en) | 2018-09-11 | 2024-03-01 | アンブルックス，インコーポレイテッド | Interleukin-2 polypeptide conjugates and uses thereof |
| US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
| AU2019361206A1 (en) | 2018-10-19 | 2021-06-03 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020131871A1 (en) * | 2018-12-19 | 2020-06-25 | Tangible Science, Inc. | Systems and methods of treating a hydrogel-coated medical device |
| MX2021007843A (en) | 2018-12-28 | 2021-08-11 | Vertex Pharma | Modified urokinase-type plasminogen activator polypeptides and methods of use. |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| EP3914289A1 (en) | 2019-01-23 | 2021-12-01 | Massachusetts Institute of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| JP2022520792A (en) | 2019-02-12 | 2022-04-01 | アンブルックス，インコーポレイテッド | Compositions, Methods, and Uses Containing Antibody-TLR Agonist Conjugates |
| AU2020258482A1 (en) | 2019-04-18 | 2021-10-14 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides |
| WO2020219323A1 (en) | 2019-04-26 | 2020-10-29 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
| WO2021126827A1 (en) | 2019-12-16 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
| WO2021127493A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
| JP7303391B2 (en) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | Biased IL2 muteins, methods, and compositions |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| KR20220148869A (en) | 2020-03-04 | 2022-11-07 | 다나-파버 캔서 인스티튜트 인크. | Structurally stabilized antiviral SARS-CoV-2 peptides and uses thereof |
| CA3174114A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| WO2021216845A1 (en) | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
| WO2021222243A2 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
| US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| JP2023538071A (en) | 2020-08-20 | 2023-09-06 | アンブルックス，インコーポレイテッド | Antibody-TLR agonist conjugates, methods and uses thereof |
| WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| US20240002450A1 (en) | 2020-11-05 | 2024-01-04 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
| CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
| CA3231587A1 (en) | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
| EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
| WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
| WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
| WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784524A (en) * | 1971-06-25 | 1974-01-08 | Grace W R & Co | Urethane/thioether-containing polyene composition and the reaction product thereof |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH586739A5 (en) * | 1973-10-17 | 1977-04-15 | Hoechst Ag | |
| US4134887A (en) * | 1973-10-17 | 1979-01-16 | Hoechst Aktiengesellschaft | Phenyl-azo-phenyl dyestuffs |
| US4179387A (en) * | 1974-03-12 | 1979-12-18 | Fuji Photo Film Co., Ltd. | Process for producing magnetic FE oxide |
| IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| DE2607766C3 (en) * | 1976-02-26 | 1978-12-07 | Behringwerke Ag, 3550 Marburg | Process for the production of carrier-bound biologically active substances |
| US4228019A (en) * | 1978-06-19 | 1980-10-14 | Texaco Development Corp. | Secondary recovery process |
| US4473693A (en) * | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
| US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| US4296097A (en) * | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
| US4430260A (en) * | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
| US4241199A (en) * | 1979-09-18 | 1980-12-23 | Union Carbide Corporation | Novel polyester diols |
| US4280979A (en) * | 1979-09-18 | 1981-07-28 | Union Carbide Corporation | Copolymers, compositions, and articles, and methods for making same |
| JPS585320A (en) * | 1981-07-01 | 1983-01-12 | Toray Ind Inc | Graft copolymer |
| US4973493A (en) * | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
| JPS59204144A (en) * | 1983-04-12 | 1984-11-19 | Daikin Ind Ltd | Novel fluorine-containing compound and production and use thereof |
| SE470099B (en) * | 1984-05-17 | 1993-11-08 | Jerker Porath | Sulfone activated thioether adsorbents for separation of eg protein |
| SE454885B (en) * | 1984-10-19 | 1988-06-06 | Exploaterings Ab Tbf | POLYMER COATED PARTICLES WITH IMMOBILIZED METAL ZONES IN ITS SURFACE PROCEDURES FOR PRODUCING THEREOF |
| US4616644A (en) * | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
| DE3675588D1 (en) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
| US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3676670D1 (en) * | 1985-06-26 | 1991-02-07 | Cetus Corp | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION. |
| US4883864A (en) * | 1985-09-06 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Modified collagen compound and method of preparation |
| US4983494A (en) * | 1985-10-16 | 1991-01-08 | Fuji Photo Film Co., Ltd. | Image forming process including heating step |
| CA1283046C (en) * | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
| US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4871785A (en) * | 1986-08-13 | 1989-10-03 | Michael Froix | Clouding-resistant contact lens compositions |
| DE3628717A1 (en) * | 1986-08-23 | 1988-02-25 | Agfa Gevaert Ag | HARDENER FOR PROTEINS, A HARDENED BINDER LAYER AND A PHOTOGRAPHIC RECORDING MATERIAL CONTAINING SUCH A LAYER |
| US4931544A (en) * | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
| DE3634525A1 (en) * | 1986-10-10 | 1988-04-21 | Miles Lab | TEST MEANS AND INDICATORS FOR DETECTING THIOL GROUPS AND METHOD FOR THE PRODUCTION THEREOF |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| NL8800577A (en) * | 1988-03-08 | 1989-10-02 | Stichting Tech Wetenschapp | METHOD FOR APPLYING A BLOOD COMPATIBLE COATING TO POLYETHERURETHANE FORMS. |
| GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| GB8824592D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Purification process |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5171264A (en) * | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| DE69120821T2 (en) * | 1990-08-31 | 1997-01-23 | Univ Minnesota | Polyethylene glycol derivatives for solid phase applications |
| US5380536A (en) * | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
| SE467308B (en) * | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | SOLID SURFACE COATED WITH A HYDROPHILIC SURFACE WITH COVALENTLY BONDED BIOPOLYMERS, SET TO MAKE SUCH A SURFACE AND CONJUGATED THEREOF |
| DE69230789T3 (en) * | 1991-01-18 | 2007-10-31 | Amgen Inc., Thousand Oaks | METHODS OF TREATING ILLNESSES RELEASED BY THE TUMOR NEKROSE FACTOR |
| ATE240740T1 (en) * | 1991-03-15 | 2003-06-15 | Amgen Inc | PEGYLATION OF POLYPEPTIDES |
| JPH06506217A (en) * | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers |
| DK52791D0 (en) * | 1991-03-22 | 1991-03-22 | Kem En Tec As | ADSORPTION MATRIX |
| JP3340434B2 (en) * | 1991-07-04 | 2002-11-05 | ダコ アクティーゼルスカブ | Water-soluble polymer-based reagents and conjugates comprising components derived from divinyl sulfone |
| DK130991D0 (en) * | 1991-07-04 | 1991-07-04 | Immunodex K S | POLYMER CONJUGATES |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| EP0622394A1 (en) * | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
-
1993
- 1993-11-12 US US08/151,481 patent/US5446090A/en not_active Expired - Lifetime
-
1994
- 1994-11-14 CA CA002176203A patent/CA2176203C/en not_active Expired - Fee Related
- 1994-11-14 ES ES95901226T patent/ES2173943T3/en not_active Expired - Lifetime
- 1994-11-14 CZ CZ19961375A patent/CZ295640B6/en not_active IP Right Cessation
- 1994-11-14 DE DE69430317T patent/DE69430317T2/en not_active Expired - Lifetime
- 1994-11-14 UA UA96062250A patent/UA58481C2/en unknown
- 1994-11-14 SK SK608-96A patent/SK284527B6/en not_active IP Right Cessation
- 1994-11-14 EE EE9600128A patent/EE03448B1/en not_active IP Right Cessation
- 1994-11-14 RO ROA200000307A patent/RO121855B1/en unknown
- 1994-11-14 AU AU10548/95A patent/AU687937B2/en not_active Ceased
- 1994-11-14 AT AT95901226T patent/ATE215577T1/en not_active IP Right Cessation
- 1994-11-14 HU HU9601253A patent/HU225649B1/en not_active IP Right Cessation
- 1994-11-14 EP EP95901226A patent/EP0728155B1/en not_active Expired - Lifetime
- 1994-11-14 NZ NZ276313A patent/NZ276313A/en not_active IP Right Cessation
- 1994-11-14 KR KR1019960702507A patent/KR100225746B1/en not_active IP Right Cessation
- 1994-11-14 PL PL94314298A patent/PL180149B1/en not_active IP Right Cessation
- 1994-11-14 BR BR9408048A patent/BR9408048A/en not_active Application Discontinuation
- 1994-11-14 RO RO96-00959A patent/RO118434B1/en unknown
- 1994-11-14 JP JP07514031A patent/JP3114998B2/en not_active Expired - Lifetime
- 1994-11-14 RU RU96113123/04A patent/RU2176253C2/en active
- 1994-11-14 WO PCT/US1994/013013 patent/WO1995013312A1/en active IP Right Grant
- 1994-11-14 DK DK95901226T patent/DK0728155T3/en active
- 1994-11-14 EP EP01122161A patent/EP1176160A3/en not_active Withdrawn
- 1994-11-14 CN CN94194460A patent/CN1085689C/en not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/473,734 patent/US5739208A/en not_active Expired - Lifetime
-
1996
- 1996-05-06 BG BG100568A patent/BG63399B1/en unknown
- 1996-05-10 NO NO19961918A patent/NO315377B1/en not_active IP Right Cessation
- 1996-05-10 FI FI962004A patent/FI117441B/en not_active IP Right Cessation
-
1998
- 1998-02-23 US US09/027,679 patent/US5900461A/en not_active Expired - Lifetime
-
1999
- 1999-04-19 US US09/294,188 patent/US6610281B2/en not_active Expired - Fee Related
-
2002
- 2002-05-30 HK HK02104035.7A patent/HK1042312A1/en unknown
-
2003
- 2003-08-25 US US10/647,621 patent/US6894025B2/en not_active Expired - Fee Related
-
2005
- 2005-04-22 US US11/112,118 patent/US7214366B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2176203C (en) | Water soluble active sulfones of poly(ethylene glycol) | |
| US8003742B2 (en) | Polymer derivatives with proximal reactive groups | |
| KR20030068178A (en) | Synthesis of high molecular weight non-peptidic polymer derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |